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Vitamin D Levels Affect Survival in a BCR-ABL Acute Lymphoblastic Leukemia
Mouse Model but Do Not Cause Vitamin-Drug Interactions
Abstract
It is a well-established phenomenon that dietary components containing CYP3A inducers or inhibitors if
co-administered with drugs that are CYP3A4 substrates lead to marked drug-drug interactions. Because
vitamin D is known to regulate intestinal CYP3A expression and gut CYP3A expression plays an important
role in pre-systemic metabolism of CYP3A drugs, we determined the impact of vitamin D (VD3) status on
systemic exposure and efficacy of chemotherapeutic agents that are CYP3A substrates. We employed
VD3 sufficient and deficient mice to perform pharmacokinetics (PK) and anti-leukemic efficacy studies.
First, using hCYP3A4 transgenic mouse model we evaluated the intestinal, hepatic and renal expression
of hCYP3A4, mouse CYPs and transporters in VD3 sufficient vs. deficient mice. We observed that female
VD3 deficient mice had significantly lower duodenal mouse Cyp3a11 and hCYP3A4 expression than VD3
sufficient mice. Since intestinal CYP3A plays a significant role in first pass metabolism of drugs that are
administered orally, chemotherapeutic agents such as dexamethasone (DEX) and dasatinib which are
given orally to the patients were chosen to study the effect of VD3 status on systemic exposure of these
CYP3A4 substrates.
In C57BL/6 mice, we performed dexamethasone PK study, where we observed male VD3 deficient mice
had higher plasma DEX levels compared to sufficient mice on day 3.5. No significant differences were
observed in females.
Another CYP3A4 substrate, dasatinib PK was also performed where AUC’s were not significantly different
between groups. However, during early absorption at t = 0.25 hr, VD3 deficient male mice had significantly
higher dasatinib plasma levels compared to VD3 sufficient mice. In conclusion, VD3 levels (sufficient vs.
deficient) significantly altered intestinal Cyp3a expression in female hCYP3A4 mice, and in male’s, plasma
exposure was different for orally administered DEX at 3.5 days, dasatinib at 0.25 hr. Ultimately, there was
no significant effect of VD3 status on DEX or dasatinib PK indicating no potential vitamin drug
interactions. However, DEX being a potential CYP3A inducer, we also observed significant induction of
multiple mouse Cyp3a’s in intestine of VD3 deficient but not VD3 sufficient mice. This differential
induction of Cyp3a’s due to vitamin D status could lead to drug interactions with other co-administered
CYP3A substrates.
Given the high prevalence of VD3 deficiency in acute lymphoblastic leukemia (ALL) patients, we evaluated
the effect of vitamin D deficiency on survival outcome from pre-B cell Arf -/- BCR-ABL acute lymphoblastic
leukemia in a murine model. Vitamin D sufficient mice died earlier (p
To investigate the mechanism by which vitamin D affected the survival and disease growth in VD3
sufficient mice, we performed in vitro studies and demonstrated 1, 25-dihydroxy vitamin D (1,
25-(OH)2VD3) increased the number of BCR-ABL ALL cells only when co-cultured with bone marrow
stroma. 1, 25-(OH)2VD3 induced CXCL12 production in vivo and in vitro in bone marrow stromal cells and
CXCL12 increased stromal migration and the number of BCR-ABL blasts. Vitamin D together with ALL
reprogrammed the marrow environment by increasing production of Type I and V collagens, potentially
trapping ALL blasts and CXCL12 expression to support tumor progression and leukemia cell homing.
In conclusion, although vitamin D deficiency did not cause significant interactions with anti-leukemic
CYP3A4 substrates, there was a significant effect on disease progression and survival of mice from BCRABL ALL.
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ABSTRACT

It is a well-established phenomenon that dietary components containing CYP3A
inducers or inhibitors if co-administered with drugs that are CYP3A4 substrates lead to
marked drug-drug interactions. Because vitamin D is known to regulate intestinal CYP3A
expression and gut CYP3A expression plays an important role in pre-systemic
metabolism of CYP3A drugs, we determined the impact of vitamin D (VD3) status on
systemic exposure and efficacy of chemotherapeutic agents that are CYP3A substrates.
We employed VD3-sufficient and -deficient mice to perform pharmacokinetics (PK) and
anti-leukemic efficacy studies.
First, using hCYP3A4 transgenic mouse model we evaluated the intestinal,
hepatic and renal expression of hCYP3A4, mouse CYPs and transporters in VD3
sufficient versus VD3 deficient mice. We observed that female VD3 deficient mice had
significantly lower duodenal mouse Cyp3a11 and hCYP3A4 expression than VD3
sufficient mice. Since intestinal CYP3A plays a significant role in first pass metabolism
of drugs that are administered orally, chemotherapeutic agents such as dexamethasone
(DEX) and dasatinib which are given orally to the patients were chosen to study the
effect of VD3 status on systemic exposure of these CYP3A4 substrates.
In C57BL/6 mice, we performed DEX PK study, where we observed male VD3
deficient mice had higher plasma DEX levels compared to sufficient mice on day 3.5. No
significant differences were observed in females.
Another CYP3A4 substrate, dasatinib PK was also performed where AUC’s were
not significantly different between groups. However, during early absorption at t = 0.25
hr, VD3 deficient male mice had significantly higher dasatinib plasma levels compared to
VD3 sufficient mice. In conclusion, VD3 levels (sufficient versus deficient) significantly
altered intestinal Cyp3a expression in female hCYP3A4 mice, and in male’s, plasma
exposure was different for orally administered DEX at 3.5 days, dasatinib at 0.25 hr.
Ultimately, there was no significant effect of VD3 status on DEX or dasatinib PK
indicating no potential vitamin drug interactions. However, DEX being a potential
CYP3A inducer, we also observed significant induction of multiple mouse Cyp3a’s in
intestine of VD3 deficient but not VD3 sufficient mice. This differential induction of
Cyp3a’s due to vitamin D status could lead to drug interactions with other coadministered CYP3A substrates.
Given the high prevalence of VD3 deficiency in acute lymphoblastic leukemia
(ALL) patients, we evaluated the effect of vitamin D deficiency on survival outcome
from pre-B cell Arf -/- BCR-ABL acute lymphoblastic leukemia in a murine model.
Vitamin D sufficient mice died earlier (p<0.003) compared to vitamin D deficient mice.
To investigate the mechanism by which vitamin D affected the survival and
disease growth in VD3 sufficient mice, we performed in vitro studies and demonstrated 1,
25-dihydroxy vitamin D (1, 25-(OH)2VD3) increased the number of BCR-ABL ALL cells
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only when co-cultured with bone marrow stroma. 1, 25-(OH)2VD3 induced CXCL12
production in vivo and in vitro in bone marrow stromal cells and CXCL12 increased
stromal migration and the number of BCR-ABL blasts. Vitamin D together with ALL
reprogrammed the marrow environment by increasing production of Type I and V
collagens, potentially trapping ALL blasts and CXCL12 expression to support tumor
progression and leukemia cell homing.
In conclusion, although vitamin D deficiency did not cause significant
interactions with anti-leukemic CYP3A4 substrates, there was a significant effect on
disease progression and survival of mice from BCR-ABL ALL.
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CHAPTER 1.

INTRODUCTION

Cytochrome P450s (CYP) play significant roles in detoxification of many
exogenous chemicals, drugs and toxins. These enzymes have broad substrate specificity
and metabolize various endogenous and natural products as well. CYP’s are not only
involved in drug disposition but also contribute significantly to first-pass metabolism of
many drugs. Various drugs and endogenous compounds like vitamin D can
transcriptionally induce CYP3A. Depending on the dose and route of inducing agents, the
extent of intestinal and hepatic induction may differ. Moreover, intestinal CYP3A
expression is sensitive to seasonal changes correlating with seasonal vitamin D levels
(Thirumaran et al., 2012). Consequently the induction of CYP’s can lead to decreased
oral bioavailability of many drugs that are metabolized by CYP3A (Kaminsky & Fasco,
1991). The following chapter highlights the role of vitamin D in transcriptional regulation
of cytochrome P450s through various receptors and associated drug interactions.

Overview of Vitamin D

Vitamin D Bioactivation
Vitamin D (VD3) is a seco-steroid hormone which can be synthesized from 7dehydrocholesterol when skin is exposed to ultraviolet radiation. VD3 is hydroxylated in
the liver into 25-hydroxy vitamin D (25-(OH)VD3) by two different vitamin D-25hydroxylases (R. Kumar, 1984): CYP27A1, CYP2R1 which are present in hepatic
microsomes and mitochondria. 25-(OH)VD3 is the major circulating form of VD3 (Henry
& Norman, 1984) and it tightly binds to vitamin D binding protein (DBP) in the plasma.
It has a long plasma half-life (~14 days) and is generally used as a measure of vitamin D
status (Holick, 2007). 25-(OH)VD3 is further hydroxylated into a biologically active
form, 1,25-dihydroxy vitamin D (1,25-(OH)2VD3) mainly by CYP27B1 in kidney
(Hewison et al., 2007). However, CYP27B1 is also expressed in extra-renal tissues such
as intestinal epithelial cells, keratinocytes, dendritic cells, cancer cells etc. where 1,25(OH)2VD3 is locally formed (Feldman, Krishnan, Swami, Giovannucci, & Feldman,
2014; Gao, Liao, Han, Thummel, & Mao, 2018). Well known intestinal effects mediated
by 1,25-(OH)2VD3 could be a result of local bioactivation of VD3 via. CYP27B1 (Gawlik
et al., 2015). CYP27B1 not only increases 1,25-(OH)2VD3 levels but also decreases its
metabolite, 24,25-(OH)2VD3 levels by converting it into 1,24,25-(OH)3VD3 (Inouye &
Sakaki, 2001).

Vitamin D Inactivation
Both 25-(OH)VD3 and 1,25-(OH)2VD3 are converted into polar metabolites via
two specific pathways, the first step being the hydroxylation of 1,25-(OH)2VD3 to
1,24R,25-(OH)3VD3 and further oxidation leading to a terminal product, calcitroic acid
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(Endres & DeLuca, 2001). CYP24A1 (24-hydroxylase) is the enzyme that catalyzes the
hydroxylation at C-24 and C-23 positions of vitamin D metabolites, which is
physiologically the main route of vitamin D degradation (Christakos, Dhawan, Verstuyf,
Verlinden, & Carmeliet, 2016). CYP24A1 is the mitochondrial P450 mainly expressed in
kidney and other vitamin D target tissues such as intestine (R. Kumar, 1984) and bone
(Turner et al., 1980). The other P450 enzyme which can also metabolize 1,25-(OH)2VD3
was later reported to be CYP3A4 contributing to form 23R- and 24S- hydroxy
metabolites, which are stereo chemically opposite to the metabolites produced by
CYP24A1 (Xu et al., 2006). Hydroxylation at C-23 is preferred by CYP3A4 and
represents a dominant pathway of 1,25-(OH)2VD3 metabolism in liver and intestine.

Vitamin D Regulation
Target cells of vitamin D have the ability to regulate its metabolism at the cellular
level indicating the importance of cellular concentration of 1,25(OH)2VD3 by which
tissues regulate their responsiveness to vitamin D (G. Jones, Strugnell, & DeLuca, 1998).
Moreover, vitamin D bio-activation and degradation is tightly regulated to maintain
appropriate levels of active vitamin D and its physiological effects (G. Jones et al., 1998).
For example, 1,25-(OH)2VD3 can itself stimulate CYP24A1 to increase its metabolism
whereas low calcium and parathyroid hormone (PTH) levels can inhibit CYP24A1 to
maintain the active vitamin D levels (Christakos et al., 2016). Similar to this negative
feedback mechanism in kidney, CYP3A4 is also prone to negative feedback mechanism
by constitutive 1,25-(OH)2VD3 in intestine (Xu et al., 2006). It has been reported that
1,25-(OH)2VD3 can regulate intestinal Cyp3a in mice (Makishima et al., 2002),
suggesting that induction of CYP3A4 by 1,25(OH)2VD3 can in turn result in enhanced
metabolism of 1,25(OH)2VD3 itself, thereby mitigating the extent of its cellular effects.

Vitamin D and Vitamin D Receptor
Different forms of vitamin D can bind to DBP which transports vitamin D
between tissues such as liver, kidney, skin and to various target tissues including intestine
and bone. When the biologically active form of vitamin D, 1,25-(OH)2VD3 enters plasma,
it is taken up by target tissues expressing a cytosolic receptor known as the vitamin D
receptor (VDR). 1,25(OH)2VD3 binds to VDR with high affinity, generally in the range
of 10-10 M (DeLuca & Schnoes, 1976).
VDR (NR1I2) belongs to nuclear receptor (NR) superfamily and acts as a
transcription factor when ligand activated. When 1,25-(OH)2VD3 binds to VDR, the
complex forms a heterodimer with the retinoid X receptor (RXR) and binds to vitamin D
response elements (VDREs) on target DNA sequence with high affinity. Following this,
recruitment of transcriptional coactivators, such as steroid receptor activator 1, 2, 3
(SRC-1, SRC-2, SRC-3) that has histone acetylase activity (HAT), is required to either
activate or repress transcription of target genes. These coactivators bind to the AF2
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domain of the liganded VDR and act as master regulators of 1,25-(OH)2VD3 action
(Christakos et al., 2016; Haussler et al., 2013).
VDR is expressed in many tissues in vivo but at relatively low levels compared to
its main target tissues such as bone, kidney and intestine which have high VDR
expression (Dame, Pierce, & DeLuca, 1985). It is also expressed in immune cells,
specially T-cells where it modulates interleukin -2 (IL-2) levels (Dame et al., 1985).

Overview of Vitamin D

CYP3A4/Cyp3a Gene
CYP enzymes are a superfamily of hemeproteins that metabolize a wide range of
xenobiotics including therapeutic drugs, toxins, carcinogens as well as endogenous
molecules (Nebert & Russell, 2002). Three P450 families CYP1, CYP2, CYP3 are
currently known to be involved in drug metabolism (Furge & Guengerich, 2006). In
humans, the CYP3A subfamily is critical for drug clearance and is reported to metabolize
at least 50% of the currently prescribed drugs (Y. T. Liu, Hao, Liu, Wang, & Xie, 2007)
(Guengerich, 2008). The CYP enzymes not only play a significant role in therapeutic
drug metabolism and disposition, but they are also responsible for many adverse drug
reactions. Clinical data suggests sex and age dependent tissue distribution of CYP
enzymes and huge interindividual variability.

Localization of CYP3A4/Cyp3a
Most CYP enzymes are highly expressed in tissues involved in absorption,
metabolism and excretion such as liver, small intestine and kidney. Almost 70% of
human P450’s is composed of CYP1A2, 2A6, 2B6, 2C, 2D6, 2E1 and 3A isoforms.
CYP3A4, CYP3A5, CYP3A7 and CYP3A43 are the four isoforms of the CYP3A family
among which CYP3A4 and CYP3A5 account for almost 30% and 20% of total P450
respectively. In humans, CYP3A4 is highly expressed in mucosal epithelium of
duodenum and jejunum (Paine et al., 1997) (Watkins et al., 1985). It is also
predominantly expressed in normal liver (Achour, Barber, & Rostami-Hodjegan, 2014).
Hepatic distribution of CYP’s is relatively homogenous compared to small intestine
where both the content and activity of CYPs is higher in the proximal than the distal
regions.
In mice, the Cyp3a family genes were primarily detected in liver and intestine.
Liver expresses high levels of at least six out of eight Cyp3a isoforms Cyp3a11, 3a16,
3a25, 3a41a/b, 3a44 and 3a59 in mice. Whereas, Cyp3a11 is the most highly expressed
Cyp3a in intestine compared to other Cyp3a’s, expression of Cyp3a13 is higher in
intestine than liver, and Cyp3a59 is higher in testis than liver. Similar to humans, mouse
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hepatic Cyp3a exhibit sexual dimorphism with females expressing predominantly
Cyp3a16, 41a/b, 3a44 and 3a59.(Renaud, Cui, Khan, & Klaassen, 2011).

Regulation of CYP3A
Nuclear hormone receptors (NR) such as the pregnane X receptor (PXR) (or NR
subfamily 1, group 1, member 2, NR1I2), constitutive androstane receptor (CAR) (or NR
subfamily 1, group 1, member 3, NR1I3) and VDR (or NR subfamily 1, group 1, member
1, NR1I1) are known to play a significant role in the regulation of CYP3A genes. PXR
and CAR are regarded as xenosensors regulating detoxification and elimination of
xenobiotics or toxic endogenous substances from the body (Mackowiak & Wang, 2016).
Interestingly the other NR1 family member VDR also regulates numerous drugmetabolizing enzymes (Pavek & Dvorak, 2008). Unlike VDR, PXR is highly expressed
in liver, but also in intestine and to a lesser extent in kidney (Pavek, 2016). Studies have
reported that PXR is involved in the regulation of other CYPs such as CYP2B6, 2C9,
2C29, 3A5, 3A7 and transporters such as UGT1A1, P-glycoprotein (Pavek & Dvorak,
2008).
As suggested by recent studies PXR and CAR have the potential to cross-regulate
CYP3A expression by different mechanisms either by sharing some ligands which could
result in dual activation or binding of PXR and CAR to common target DNA response
elements. But it has been reported that PXR is a dominant regulator of CYP3A
expression compared to CAR (Goodwin, Hodgson, & Liddle, 1999).
Endogenous compounds and xenobiotics that are substrates to these NR’s regulate
CYP3A expression and contribute to huge inter individual variability in humans.
Numerous other factors including genetic and environmental could contribute to the
inter-individual variability of intestinal CYP3A4 but cannot explain it completely. Many
studies reported clinically observed variability in intestinal CYP3A expression (Lown et
al., 1994; Paine et al., 2005; Xu et al., 2006). Pharmacokinetics and pharmacodynamics
of many drugs that are CYP3A4 substrates can be influenced by this variability (Gorski et
al., 1998; Thummel et al., 1996) which can influence the extent of drug absorption,
metabolism and elimination thereby altering the therapeutic efficacy or toxic response of
the drug.

Substrates and Inducers of CYP3A

Substrates
The CYP3A family of enzymes are known to metabolize a variety of clinical
drugs including macrolide antibiotics such as rifampin and naturally occurring and
synthetic glucocorticoids such as dexamethasone (DEX). However, xenobiotic exposure
can result in enhanced or repressed transcription of both intestinal and hepatic CYP3A.
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Many of CYP3A substrates can also induce CYP3A expression. For example, DEX is
both substrate and inducer of CYP3A4.

Inducers
Steroid hormones including glucocorticoid agonists and antagonists, macrolide
antibiotics, imidazole antifungals, phenobarbital, polychlorinated biphenyls and organic
pesticides are known to induce CYP3A transcription (Gonzalez, Liu, & Yano, 1993).
Drugs such rifampin, phenobarbital, glucocorticoids can induce mouse Cyp3a11,
Cyp3a13 and human CYP3A4 in vivo and in cultured hepatocytes (Schuetz, Wrighton,
Barwick, & Guzelian, 1984; Watkins et al., 1985; Wrighton et al., 1985; Yanagimoto,
Itoh, Sawada, & Kamataki, 1997). The CYP2B family genes are also normally induced
by many of these same drugs (Honkakoski & Negishi, 1998; Strom et al., 1996). These
interactions lead to clinically important drug-drug interactions when these inducer drugs
are co-administered with CYP substrates (such as cyclosporin A, midazolam etc.).

Species Differences
Marked species differences exist regarding CYP3A induction. For example, in
humans, rifampin causes a 10-fold induction of CYP3A (Strolin Benedetti & Dostert,
1994), whereas only a 2-fold induction in mice (Tredger, Smith, Powell-Jackson, Davis,
& Williams, 1981). Pregnenolone-16a-carbonitrile (PCN) is a strong inducer of rat
CYP3A but not human.

Role of PXR, GR in CYP3A Induction
PXR is the main receptor involved in the steroid and drug induction of CYP3A
(Kliewer et al., 1998). High concentrations of DEX and phenobarbital ligand activate
both mouse and human PXRs to induce CYP3A. There is no role for the glucocorticoid
receptor (GR) in CYP3A induction. Glucocorticoids and anti-glucocorticoids follow the
non-classic glucocorticoid induction pathway and induce CYP3A genes (Schuetz et al.,
2000). Although glucocorticoids are both substrates and inducers of CYP3A enzymes,
they have different requirements for the glucocorticoid receptor to induce CYP3A and
CYP2B genes (Schuetz et al., 2000). In normal condition, they can bind to GR and
induce genes regulated by GR. However, when glucocorticoid levels are extremely high
(stressful conditions) or when high doses are given, they can produce maximum CYP3A
induction through activation of PXR (Yusim, Franklin, Brooke, Ajilore, & Sapolsky,
2000). The dose required to activate PXR is usually at least 100-fold higher (Reid, 1997)
than that required to activate GR. Physiologically, this feedback mechanism of PXR
mediated CYP3A induction is to regulate the levels of corticosteroids and maintain
steroid homeostasis to prevent any tissue damage during stressful conditions (H. Zhang et
al., 1999) (Collier, Wu, & Pruett, 1998). The significant difference in the ligand binding
domain (LBD) of PXR across species is responsible for the species differences in
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induction of CYP3A – e.g., rifampin potently activates the LBD of human PXR, but is a
weak activator of rat and mouse PXR, while PCN activates rodent PXRs LBD but not
human PXR LBD.
(Schuetz et al., 1984) reported that GR might be involved in the synergistic
induction of CYP3A by PCN and DEX. This synergistic induction could be a result of
either protein-protein interaction between GR and PXR or inducers binding to
glucocorticoid response elements (GRE) present upstream of PXR/RXR binding site on
CYP3A gene. Moreover, recently it was reported that DEX treatment increased PXR and
RXR mRNA accumulation in human hepatocytes likely through GR activation, which
could also result in increased CYP3A expression (H. Zhang et al., 1999). However,
induction of PXR and RXR mRNA requires their levels in hepatocytes to be rate limiting.

Dietary Interactions with CYP3A
Significant clinical interactions due to CYP3A induction or repression of activity
by not only drugs but also dietary and natural compounds have been reported. For
example, St. John’s wort and grapefruit juice have been reported to alter CYP3A
enzymes (Bailey, Malcolm, Arnold, & Spence, 1998; Bhardwaj et al., 2002; Johnson,
Won, Kock, & Paine, 2017; Peltoniemi et al., 2012). Mechanistically, St. John’s wort
contains hyperforin one of the most potent ligand activators of PXR. Grapefruit juice
contains 6,7-dihydrobergamottin that increases proteasome mediated degradation of
intestinal CYP3A4 protein while having no effect on its mRNA. At least 20 drugs
especially those with extremely low oral bioavailability due to pre-systemic metabolism
were assessed to undergo interactions with grapefruit juice. Moreover, these interactions
differ from patient to patient based on type and amount of grapefruit juice and individual
susceptibility (Bailey et al., 1998). This indicates that dietary ingredients can also
influence the level of CYP3A expression and therefore explain partly the huge
interindividual variability in humans.
Similarly, vitamin D is also an important transcriptional regulator of CYP3A
expression, and CYP3A is sensitive to changes in vitamin D levels. Consequently,
vitamin D levels can also contribute to the CYP3A expression variability depending on
the individual vitamin D status. These vitamin D-CYP3A interactions could be of
significant importance specially when the co-administered drugs have a narrow
therapeutic index or major toxicity.

Drug Transporters
The ATP-binding cassette (ABC) family of transporters are well known efflux
transporters that transport wide range of drugs, exogenous chemicals and endogenous
substances. P-glycoprotein (PGP) is a member of ABC subfamily B member 1 (ABCB1)
which is present in multiple tissues but highly expressed in intestine (epithelial cells),
liver (hepatocytes) brain, kidney (Allen, Brinkhuis, Wijnholds, & Schinkel, 1999). It
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plays a significant role in protecting our body from toxins. Similar to CYP3A family,
transporters also have a protective function by reducing the absorption of toxic
chemicals, and hence there is a lot of substrate overlap between drug metabolizing
enzymes and transporters (Borst & Schinkel, 2013), (Cascorbi, 2011). Dexamethasone,
dasatinib, cyclosporin etc. are substrates of both CYP3A and PGP (Schinkel, Wagenaar,
van Deemter, Mol, & Borst, 1995) (Schinkel et al., 1995).
Breast cancer resistant protein (BCRP) or ABC subfamily G2 member (ABCG2)
is an efflux transporter mainly expressed in placenta, small intestine, liver, kidney, blood
brain barrier and breast (Stacy, Jansson, & Richardson, 2013). BCRP transports many
endogenous substances and a diverse groups of exogenous chemicals such as tyrosine
kinase inhibitors, anthracene drugs, statins, and proton pump inhibitors, etc. (Mao &
Unadkat, 2015; Meyer zu Schwabedissen & Kroemer, 2011).
Multidrug resistance associated protein (MRP4) or ABC subfamily C member 4
(ABCC4) is another well-known transporter that transports many endogenous and
exogenous substances. It plays a significant role in renal excretion of its substrates
(Russel, Koenderink, & Masereeuw, 2008).
Drug metabolizing enzymes and transporters are major routes of detoxification for
the drugs in the body and also share substrates and inhibitors. Therefore, they contribute
significantly to the drug-drug interactions and evaluating their expression in vitamin D
deficiency condition could provide insights into mechanisms involved in vitamin drug
interactions.

Vitamin D Deficiency
Vitamin D deficiency (VDD) is very common in a significant number of people
worldwide and is considered endemic in many parts of the world with deficiency rates
ranging from 42 to 61% in pediatric and adolescent population in the United States (J.
Kumar, Muntner, Kaskel, Hailpern, & Melamed, 2009). Although lack of exposure to
sunlight and low vitamin D intake are considered to cause vitamin D deficiency,
clinically impaired intestinal vitamin D absorption or treatment with drugs enhancing
vitamin D metabolism can also result in VDD (Glorieux & Pettifor, 2014; Prentice, 2013;
Schafer et al., 2015). Vitamin D deficiency could lead to many disorders such as type II
Rickets, increased bone fracture, etc.
Therefore, vitamin D supplementation is generally given to maintain vitamin D
levels and to increase the bone mineral density in patients. Although many clinical trials
investigated the effect of vitamin D supplementation with or without calcium to reduce
fracture incidence, there is no consensus on the benefit of supplementing vitamin D in
these patients (Bischoff-Ferrari et al., 2012; Lips, Gielen, & van Schoor, 2014).
Furthermore, there is a concern that vitamin D supplementation could cause vitamin drug
interactions with CYP3A4 substrates.
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Vitamin D – CYP3A4 Clinical Interactions
Vitamin D (VD3) deficiency leads to bone loss, decreased bone mineral density,
rickets, osteoporosis, hyperparathyroidism and increased risk of fracture (Greer, 2009).
Glucocorticoids such as DEX and prednisone are widely used clinically as part of
leukemia chemotherapy. Long term exposure to glucocorticoids is known to produce
adverse skeletal effects due to early rapid bone resorption and a late impaired bone
formation (Mazziotti, Giustina, Canalis, & Bilezikian, 2007). This adverse effect is also
attributed to increased VD3 metabolism which can be detrimental to the VD3 deficient
leukemia patients.
Vitamin D – Intestinal CYP3A4
Since intestinal CYP3A4 mediated metabolism contributes to decreased oral
bioavailability of its substrates, co-administration of VD3 (a CYP3A4 inducer) with a
CYP3A4 substrate might cause incomplete oral bioavailability of that drug substrate. On
the other hand, vitamin D deficiency could increase the oral bioavailability of CYP3A4
substrates. A study by Schwartz et al., reported increased clearance of a CYP3A4
substrate, atorvastatin in vitamin D deficient humans supplemented with VD3 (Schwartz,
2009). Another study reported seasonal variation in serum levels of CYP3A4 substrates,
tacrolimus and sirolimus that mirrored the seasonal variation in serum levels of VD3
(Lindh, 2011). Previously our lab has reported the seasonal variation of in vivo intestinal
CYP3A4 expression, correlating with seasonal VD3 levels (Thirumaran et al., 2012).
Hence, serum VD3 levels, which is associated with intestinal CYP3A4 activity,
has the potential to alter oral drug absorption and clearance. At St. Jude Children’s
Research Hospital, CYP3A4 substrates such as DEX and dasatinib are administered
orally as part of chemotherapy to ALL patients (Christopher et al., 2008; Gentile, 1996).
Dexamethasone (DEX) is a synthetic analog of cortisol used during the induction,
delayed intensification, and maintenance phases of ALL chemotherapy, most pediatric
patients receive it for about half of their 2-3 years of treatment period (Margolin JF,
2006). Because DEX is both a substrate and inducer of CYP3A, understanding the effect
of VD3 deficiency on DEX systemic exposure and evaluating any vitamin drug
interactions is necessary.
Dasatinib is a tyrosine kinase inhibitor, specifically administered to acute
lymphoblastic leukemia patients with the BCR-ABL-translocation that generates the
BCR-ABL+ oncogene that has elevated ABL kinase activity. Dasatinib can also inhibit
SRC kinase which is involved in growth and progression of many cancers. Dasatinib is
specifically approved to be used in imatinib resistant chronic myeloid leukemia and acute
lymphoblastic leukemia. The oral bioavailability of dasatinib is very low ranging from
14% in mouse to 34% in dogs. Dasatinib undergoes high first-pass metabolism by
CYP3A, both in the intestine and liver (Christopher et al., 2008). Any changes in
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intestinal CYP3A due to vitamin D status might decrease or increase the pre-systemic
metabolism of dasatinib in the gut, thereby influencing its pharmacokinetics.
Because both these drugs are administered orally, we evaluated whether changes
in pharmacokinetics and clearance of dexamethasone and dasatinib occurred due to VD3
deficiency.
In summary, small intestine is the first site of exposure to orally administered
drugs where abundant drug metabolizing CYP3A enzymes and transporter are expressed.
They are responsible for increasing or decreasing the oral bioavailability of many drugs.
Because CYP3A4 has broad substrate specificity, many drugs have the potential to
interact with CYP3A4 and cause drug-drug interactions. Most of these interactions have
been studied and reported. In spite of many reports suggesting vitamin D deficiency in
normal population as well as patients with various cancers, very little is known about
vitamin D’s interaction with CYP3A4 substrates. Because pediatric acute lymphoblastic
patients are orally administered DEX and dasatinib, substrates of CYP3A4, it was
important to determine whether supplementation of vitamin D to VD3
insufficient/deficient patients might cause a drug interaction with either substrate or
compromise anti-leukemic efficacy.
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CHAPTER 2.

VITAMIN D AND LEUKEMIA

Vitamin D in Health
Vitamin D regulates many different genes, most of which play an important role
in physiological calcium homeostasis or bone formation. These genes include
osteocalcin, osteopontin, parathyroid hormone (PTH) (Berridge, 2015). In intestine,
1,25(OH)2VD3 is known to regulate many processes such as intestinal calcium and
phosphorus transport, nuclear events such as chromatin template activity, DNAdependent RNA polymerase II activity and Ca+2 dependent ATP and alkaline
phosphatase activities (Carlberg & Campbell, 2013). Although maintaining calcium and
phosphate homeostasis is an important function of 1,25-(OH)2VD3, many studies have
demonstrated its role in other cellular processes such as proliferation, differentiation,
immune modulation in both normal and malignant cells (Berridge, 2015; Bikle, 2012).

Vitamin D in Disease
Vitamin D promotes enterocyte differentiation and intestinal calcium and
phosphorus absorption which helps in bone mineralization. Therefore, vitamin D
deficiency can significantly affect the bone mineral density both by reduced absorption
and enhanced resorption of calcium resulting in several disorders such as rickets and
osteomalacia. CYP27B1 converts 25(OH)VD3 to 1,25(OH)VD3, and mutations in this
gene resulting in inactive or deleted CYP27B1 cause vitamin D deficiency rickets type I
(VDDRI) irrespective of normal vitamin D intake. Hereditary vitamin D resistant rickets
(HVDDR or VDDRII) is another form of rickets where there is organ-resistance to
vitamin D due to heterogenous loss of function mutations in VDR (Sahay & Sahay,
2012). Because calcium and bone homeostasis are highly interlinked, studies in both mice
or humans lacking VDR or CYP27B1 has shown phenotype of rickets and osteomalacia.
In spite of differences in role of vitamin D between human and mouse models, animal
models could still help unravel complex mechanistic pathways involving similar genes
that could affect humans (Christakos et al., 2016).
Epidemiological studies suggested a role of vitamin D not only in the skeletal
system but also in cancer, cardiovascular disease, kidney disease, psoriasis etc. (Sahay &
Sahay, 2012). Many studies have reported that vitamin D deficiency is associated with
cardiovascular pathology. In humans, low vitamin D levels are associated with arterial
hypertension, diabetes mellitus and dyslipidemia (Podzolkov, Pokrovskaya, &
Panasenko, 2018). Because of vitamin D’s role in various cellular processes such
proliferation, apoptosis, ageing of cells, it has been associated with various age-related
diseases such as Alzheimer’s, Parkinson’s, multiple sclerosis diseases (Berridge, 2017).
Although laboratory studies report extra-skeletal beneficial effects of supplementing
vitamin D, it is important to obtain definite clinical data regarding the use of vitamin D
and its analogues for treatment or prevention of disease processes.
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Vitamin D in Cancer
Many cancer cells not only express VDR through which vitamin D exhibits its
effects, but also express CYP27B1 or CYP24A1, the enzymes involved in vitamin D
metabolism (Bikle, 2016). The expression of these enzymes can regulate the local
production of active VD3, which can have significant implications in cancer progression
(Hobaus, Thiem, Hummel, & Kallay, 2013; Swami et al., 2012). Several reports have
suggested VDR expression in tumor cells to be a prerequisite for antineoplastic effects of
1,25-(OH)2VD3 such as differentiation of HL60 leukemia cells into macrophages requires
VDR expression (Abe et al., 1981).

Vitamin D Deficiency in Cancer
It has been reported that at least 72% of pediatric and young adults with cancer
suffer vitamin D deficiency at diagnosis and this hypovitaminosis persists throughput the
survivorship (Choudhary, Chou, Heller, & Sklar, 2013; Helou et al., 2014; Wallace et al.,
2015). With significant proportions of cancer patients being vitamin D deficient, it
became important to understand its association with the survival outcome. Several reports
from pre-clinical as well as clinical studies show that vitamin D deficiency correlated
with poor survival outcome. Vitamin D deficient mice inoculated with tumor cells such
as colon or breast cancer had increase in tumor growth (Ooi et al., 2010; Ray et al., 2012;
Tangpricha et al., 2005). On the other hand, repression of tumor formation was observed
in rodents with sufficient vitamin D and calcium levels (Newmark et al., 2009).
In mouse xenograft models of prostrate and breast cancer, it has been reported
that vitamin D supplementation can inhibit tumor growth (Swami et al., 2012). In a preclinical study involving mice with pancreatitis, administration of calcipotriol, an analogue
of vitamin D resulted in decreased fibrosis and inflammation. Induction of extensive
stromal remodeling with reduced tumor-supportive signaling led to enhanced efficacy of
co-administered chemotherapeutic agent and increased survival of the mice (N. Ding et
al., 2013). In spite of vitamin D’s (supplementation) ability to reduce tumor growth and
metastasis, its adverse effects such as hypercalcemia hinder its clinical applicability.

Vitamin D Deficiency in Leukemia
One of the major factors leading to leukemia is perturbations in white blood cell
(T or B cell) differentiation in the bone marrow (BM) due to a combination of genetic
and environmental factors. Based on the lineage and persistence of the disease, leukemia
is classified into four major types, acute lymphoblastic leukemia (ALL), chronic
lymphoblastic leukemia (CLL), acute myeloid leukemia (AML), chronic myeloid
leukemia (CML). Considering the prevalence of VD3 deficiency in leukemia patients,
numerous researchers conducted studies to perceive the association of VD3 and clinical
outcome in different types of leukemia.
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AML is characterized by immature hematopoietic myeloid precursors that have
lost their ability to differentiate and proliferate normally (Tenen, 2003). Vitamin D
deficiency is highly prevalent in AML patients with at least 80% of the patients at
diagnosis have significantly low serum vitamin D levels (Seyedalipour et al., 2017) and
has been associated with poor survival outcome whereas high vitamin D levels with
better clinical outcome (Seyedalipour et al., 2017). AML cells, although expressing low
constitutive levels of VDR, induced VDR expression at a post transcriptional level
following treatment with 1,25-(OH)2VD3 (Gocek, Baurska, Marchwicka, &
Marcinkowska, 2012). In vitro studies using a variety of AML cell lines such as HL-60,
AML-193, NB-4, U937 etc. indicated 1,25-(OH)2VD3 treatment induced differentiation
of these cells into monocytes (Kim et al., 2012). In vivo studies using animal models with
AML and treated with vitamin D analogues suggested significantly better survival of
mice compared to the no treatment group (J. Y. Zhou et al., 1990). However, due to the
limitations and inconsistencies between the studies, it is challenging to translate vitamin
D or its analogues usage in the clinical setting (Cao et al., 2017).
Similar to AML, CLL patients also suffer with vitamin D insufficiency and that
has been associated with poor overall survival outcome. Although higher 25-(OH)VD3
levels show protective effect against development of CLL, no significant correlation
between vitamin D levels and overall risk for lymphoid cancer development has been
shown (Luczynska et al., 2013). In a study with 983 non-Hodgkin’s lymphoma (NHL)
patients comprised of subtypes including diffuse large B-cell lymphoma and T-cell
lymphoma, 44% of patients were vitamin D deficient at the time of diagnosis (Drake et
al., 2010). These insufficient serum vitamin D levels were associated with shorter event
free and overall survival specifically in these subtypes. No correlations were observed in
other NHL subtypes (Bittenbring et al., 2014).
These studies indicate the importance of measuring vitamin D levels at diagnosis,
throughout the treatment and evaluating if vitamin D has any effect on the clinical
outcome.

Vitamin D Deficiency in ALL
Approximately 60% of ALL patients are vitamin D deficient (Young et al., 2018)
and are highly prone to the adverse bone effects associated with chemotherapy. Persistent
decline in bone mineral density is observed from diagnosis until off-therapy for as long as
10-years following diagnosis in ALL patients (Demirsoy et al., 2017; Kuhl et al., 2012).
Reasons include vitamin D deficiency at diagnosis, leukemic cell infiltration, irradiation,
toxicities associated with chemotherapies such as corticosteroids and methotrexate which
are known to intensify bone resorption and decrease osteoblast function. Supportive care
measures such as antiepileptic agents also negatively impact vitamin D levels by
interacting with CYP3A4, an enzyme involved in vitamin D metabolism/inactivation
(Heaney, 2005; J. Y. Lee, So, & Thackray, 2013).
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Unlike other leukemia malignancies, association of vitamin D levels and survival
outcome has not been studied in ALL. One of the reasons for this could be that B-ALL
cells do not express VDR, which is considered to be a prerequisite for vitamin D’s antineoplastic activity. There are at least two clinical trials ((Dana Farber and Children’s
Hospital of LA (ClinicalTrials.gov Identifier number: NCT01574274 and NCT01317940,
respectively) administering vitamin D to insufficient and deficient pediatric acute
lymphoblastic leukemia patients to restore VD3 sufficiency and determine if there is
improved bone mineral density in the context of changes in body composition and body
fat. In another study children and young adult ALL patients were supplied with vitamin
D to maintain their bone mineral density and it was shown to be safe and effective in
(Young et al., 2018). Nevertheless, long term health outcomes commonly observed in
ALL patients such as osteonecrosis, fracture rate, and overall survival outcome have not
been reported.
Since a significant proportion of ALL patients are VD3 insufficient/deficient, it is
critical to evaluate the role of vitamin D status in the progression of such disorders.
Therefore, we aimed to investigate the effect of VD3 on survival from BCR-ABL ALL in
a mouse model. BCR-ABL is a fusion gene, also called Philadelphia chromosome (Ph+),
that arises from the translocation between chromosomes 9 and 22 in at least 3-5% of
pediatric ALL cases and 25% of adult ALL cases (Williams & Sherr, 2008). The
resulting BCR-ABL oncogene has much higher ABL kinase activity.

Role of Vitamin D in the Bone Marrow Microenvironment
ALL is characterized by abnormal expansion of malignant lymphoblasts that
replace hematopoietic stem cells (HSCs) from the bone marrow microenvironment
(BMM) where they reside with a multitude of other cell types which help maintain
homeostasis. HSCs tend to localize in two different niches in the bone marrow (BM), the
perivascular niche and the endosteal niche (Nombela-Arrieta et al., 2013). Leukemia cells
can migrate to the BMM similar to the HSCs (Peled et al., 1999), and can further disrupt
the healthy microenvironment in the BM by creating a leukemia niche. This niche helps
leukemia cells to proliferate better and hide from treatment and immune response
(Fujisaki et al., 2011) (Nakasone et al., 2012).
The cells in the niche produce various cytokines and cell adhesion molecules that
support lymphocyte proliferation and migration. Lymphocytes are attracted by a
chemokine called stromal cell-derived factor 1(SDF-1 or CXCL12) which is produced by
various cells in the BMM (Peled et al., 1999; van den Berk et al., 2014). CXCL12 binds
to CXCR4, a receptor expressed on the lymphocytes and attract them towards the BMM.
This CXCR4-CXCL12 axis has been shown to be important in homing of ALL cells
towards the BMM (Colmone et al., 2008; Juarez et al., 2007; Sipkins et al., 2005).
Various cell types such as perivascular stromal cells, mesenchymal stem cells (MSCs),
endothelial cells, osteoblasts, fibroblasts secrete CXCL12 (although to various degrees)
to regulate HSC maintenance (L. Ding, Saunders, Enikolopov, & Morrison, 2012). Apart
from these, CXCL12 abundant reticular cells (CARs) which can differentiate into
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osteoblasts and adipocytes also produce a significant amount of CXCL12 to help
maintain HSC self-renewal, proliferation, and migration (Omatsu et al., 2010).
Human marrow-derived stromal cells (hMSCs) or mesenchymal stem cells
include progenitors of several lineages including osteoblasts, chondrocytes and
adipocytes (Krebsbach, Kuznetsov, Bianco, & Robey, 1999; Prockop, 1997). Studies
show that treatment of hMSCs with 1,25-(OH)2VD3 resulted in increased differentiation
of hMSCs towards osteoblasts (P. Liu, Oyajobi, Russell, & Scutt, 1999). Therefore, we
investigated if vitamin D status altered the expression of CXCL12, produced by these
cells in the BMM which can play a huge role in proliferation and homing of the leukemia
cells.
Vitamin D is well known to play an important role in bone homeostasis. In
diseases such as pancreatitis and hepatic stellate cancer, vitamin D was shown to remodel
the stromal cells with reduced tumor supportive signaling (N. Ding et al., 2013) . Any
changes in the bone marrow composition due to vitamin D deficiency can lead to bone
marrow remodeling. Changes in expression of soluble factors such as chemokines,
adhesion molecule in the bone could in turn alter the bone marrow microenvironment.
Considering VD3 deficiency causes a significant bone loss and decreased bone
mineral density, it becomes critical to ascertain if vitamin D status can remodel the
BMM. Here, we aimed to evaluate the changes associated with vitamin D deficiency on
the bone marrow microenvironment. We investigated the effect of VD3 on both
proportions of various BM cell types as well as expression of chemokines regulating
tumor cell proliferation and homing to the BM that can ultimately impact the survival
outcome.

Central Hypothesis
Vitamin D insufficiency or deficiency is common worldwide in the pediatric
population, including those with leukemias. In addition, chemotherapies used to treat
leukemia’s such as glucocorticoids cause a further erosion of VD3 through induction of
CYP3A4, that metabolizes 1,25-(OH)2VD3 and 25-(OH) VD3. Given the prevalence of
VD3 deficiency in the pediatric leukemia population, clinical trials are ongoing at
multiple pediatric leukemia centers (Dana Farber Pediatric ALL, Children’s Hospital LA)
to determine whether VD3 supplementation can restore VD3 levels and help improve
bone mineral density. However, there is a concern that VD3 treatment might cause a
vitamin-drug interaction with CYP3A4 substrates because
•

VD3 is known to transcriptionally induce intestinal CYP3A4 (Thummel et al.,
2001)

•

Intestinal CYP3A4 shows seasonal variation (Thirumaran et al., 2012) and
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•

Schwartz JB et al., reported that VD3 supplementation increased atorvastatin
(CYP3A4 substrate) clearance in VD3 deficient patients (Schwartz, 2009).

Although many reports suggest an association between VD3 deficiency and poor
survival outcome in various leukemia subtypes, there is no data on the potential effect of
VD3 on survival of mice from pre-B cell leukemia.
Therefore, it is imperative to determine both the effect of VD3 on intestinal
CYP3A expression and the pharmacokinetics of orally administered CYP3A4
metabolized leukemia therapies and its effect on the efficacy of those therapies on
survival from acute lymphoblastic leukemia (ALL). Upon conclusion, we will understand
the consequences of VD3 deficiency on survival outcome in a pre-B cell leukemia and
interactions of VD3 with chemotherapeutics that are CYP3A4 substrates.
The central hypothesis of this proposal is “VD3 deficiency causes vitamin-drug
interactions with antileukemic - CYP3A4 substrates, and also affects leukemia cell
proliferation and migration leading to differential homing pattern causing an impact on
survival outcome in BCR-ABL+ Arf-/- acute lymphoblastic leukemia”. Below specific
aims (Figure 2-1) were designed to evaluate this hypothesis.

Specific Aim 1 (Chapter 3)
a. Investigate the effect of VD3 status on expression of intestinal and hepatic mouse
Cyp3a’s, human CYP3A4 and other ADME genes in intestine, liver and kidney.
b. Determine if VD3 status alters the pharmacokinetics of orally administered antileukemic-CYP3A substrates, dexamethasone and dasatinib.

Specific Aim 2 (Chapters 3 and 4)
To evaluate the effect of VD3, alone or in combination with dexamethasone on
survival of BCR-ABL+ Arf-/- ALL mouse model.

Specific Aim 3 (Chapter 4)
To determine the effect of VD3 on the bone marrow microenvironment
remodeling, and BCR-ABL Arf-/- leukemic blast migration, homing and proliferation
using in vivo and in vitro models.
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Figure 2-1.

Schematic for specific aims.
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CHAPTER 3. VITAMIN D STATUS ALTERS DRUG DETOXIFICATION
GENE EXPRESSION AND DEXAMETHASONE INDUCTION OF
CYTOCHROME P450S IN MICE

Introduction
The Cyp3a subfamily of enzymes are responsible for the metabolic transformation
of many drugs and some endogenous molecules. CYP3A4, an important member of
Cyp3a family in humans can metabolize at least 50% of the prescription drugs and is
found to be highly expressed in drug detoxification organs such as liver and small
intestine (Kolars et al., 1994). Intestinal CYP3A-mediated first-pass metabolism of orally
administered substrates such as cyclosporine, midazolam, lovastatin, felodipine,
saquinavir, and buspirone is a major basis for their low oral bioavailability (Kolars,
Awni, Merion, & Watkins, 1991) (Paine et al., 1997).
Induction of hepatic and intestinal CYP3A4 is the basis for many drug-drug
interactions. CYP3A4 is induced by nuclear hormone receptors in the NR1I family that
are each activated by specific ligands: NR1I2/Pregnane X receptor (PXR) (e.g.,
glucocorticoids, rifampicin) and NR1I3/constitutive activated receptor (CAR) (e.g.,
phenobarbital) (Chai, Cherian, Wang, & Chen, 2016) (Matsunaga et al., 2012) (Lin,
2006). We previously determined that CYP3A4 is also induced by NR1I1/Vitamin D
receptor (VDR) activated by 1,25 (OH)2VD3 (Thummel et al., 2001), although this
induction occurs primarily in intestinal enterocytes where VDR is highly expressed
versus hepatocytes where it is lowly expressed (Matsubara et al., 2008).
Several lines of evidence suggest vitamin D could cause a vitamin-drug
interaction (VDI) with CYP3A4. (Lindh, 2011) showed in humans that systemic
exposure of the immunosuppressant CYP3A4 substrates sirolimus and tacrolimus varied
seasonally (higher in winter than summer), correlating with sunlight exposure and
vitamin D levels. We showed that human intestinal biopsy CYP3A4 expression varied
seasonally with sunlight and vitamin D levels (higher in Spring/Summer and lower in
Fall/Winter) and corresponded with a higher systemic midazolam level in patients dosed
in winter versus summer (Thirumaran et al., 2012). (Schwartz, 2009) showed that vitamin
D deficient patients given vitamin D supplementation had increased clearance of the
CYP3A4 substrate atorvastatin.
Vitamin D deficiency or insufficiency is common in patients with acute leukemias
(Naz, R, T, & Mahboob, 2013). Approximately 60% of acute lymphoblastic leukemia
(ALL) patients at diagnosis are vitamin D insufficient or deficient, with deficiency and
insufficiency more common in winter than summer (Young et al., 2018). Vitamin D
deficiency in leukemia patients in combination with long term glucocorticoid therapy
leads to reduction in bone mineral density (BMD) (Demirsoy et al., 2017). Some of these
patients are prescribed VD3 supplementation to maintain VD3 levels and restore BMD
(Orgel et al., 2017). Although intestinal Cyp3a expression can be regulated by VD3 and
many chemotherapeutic agents are Cyp3a substrates, it has not yet been determined
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whether vitamin D sufficiency versus deficiency would affect the systemic concentrations
of these chemotherapies. In this study we determined whether vitamin D sufficient versus
deficient mice (a) differ in intestinal expression of VDR target genes, such as Cyp3a, or
(b) differ in systemic exposure to the orally administered Cyp3a metabolized leukemia
therapies DEX and dasatinib, or (c) differ in DEX’s anti-leukemic efficacy.

Methods

Animals
Association for Assessment and Accreditation for Laboratory Animal Care
(AALAC) guidelines were followed for all experimental animal procedures and housing,
all protocols were approved by Institutional Animal Care and Use Committee (IACUC).
E5-E6 pregnant C57BL/6J female mice were kept on the VD3 deficient (Harlan catalog
no. 5A69, 0 IU of vitamin D) and VD3 sufficient diets, (catalog. No. 5BV8, 3.3 IU of
vitamin D) to develop vitamin D deficient and vitamin D sufficient mice (Figure 3-1),
respectively. Pregnant dams were maintained on these diets throughout pregnancy, and
after parturition, and pups were maintained on the corresponding diets after weaning as
described in (Annu et al., 2020). The pups were age matched and both male and female,
VD3 deficient and VD3 sufficient mice were used for Cyp3a expression, pharmacokinetic
and efficacy studies. For BCR-ABL survival studies with DEX treatment, C57BL/6J
sufficient mice were placed on VD3 deficient and VD3 sufficient diets beginning at
weaning.
To observe the effect of vitamin D status on hCYP3A4 expression, cryopreserved
hCYP3A4 transgenic (tg) mouse sperm was used to re-derive the humanized CYP3A4
transgenic mouse model (Granvil et al., 2003). E5-E6 pregnant hCYP3A4-tg female mice
were kept on VD3 deficient and sufficient diets throughout pregnancy and after
parturition as described for C57BL/6J mice. Pups were maintained on the corresponding
diets after weaning and were euthanized at 8 and 12 weeks of age for tissues, blood was
collected by cardiac puncture and serum isolated and stored at -80ºC for 25-OH-VD3
analysis. Vitamin D deficiency in the mice was confirmed by analyzing serum
25(OH)VD3 levels in randomly selected mice in all studies (Table 1) and sent to the
Veterinary Diagnostic Laboratory at Michigan State University (Lansing, MI) for 25(OH) VD3 analysis. Intestine (duodenum), liver and kidney were harvested and stored in
RNA later at -20C.

mRNA Quantification by Real-time PCR
Mouse intestine (duodenum), liver and kidney tissues stored in RNA later at 20C were used for RNA isolation. Trizol (Ambion Life technologies, CA, USA or
Thermo Fisher scientific, CA, USA) was used to extract RNA according to the
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Figure 3-1.
mice.

Design to develop age-controlled vitamin D-sufficient and -deficient
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manufacturers protocol. Sterile Omni tips (OMNI International, GA, USA) were used to
homogenize the tissue using Omni tissue homogenizer. 500 ng of RNA was used to
generate cDNA using the ThermoscriptTM RT-PCR system (Invitrogen ThermoFisher,
CA, USA). The cDNA was diluted to a total volume of 70 L. Primers used for the
amplification:
mCyp3a11 (F) CTGGGCCCAAACCTCTGCCA
mCyp3a11 (R) TGTGACAGCAAGGAGAGGCGT
mCyp3a13 (F) TACCCCAGTATTTGATGCAC
mCyp3a13 (R) AGATAACTGACTGAGCCACA
mMdr1a (F) TGCCACCACGATCGCCGAGA
mMdr1a (R) TCAGCTGCGCCCCTCTCTCA
mBcrp (F) CCATAGCCACAGGCCAAGT
mBcrp (R) GGGCCACATGATTCTTCCAC
hCYP3A4 (F) CACAGATCCCCCTGAAATTAAGCTTA
hCYP3A4 (R) AAAATTCAGGCTCCACTTACGGTG
mCyp2b10 (F) CTTGCGCCTGCTGGAGCTGT
mCyp2b10 (R) GGTCCAAGGTGGCCCTGTGC
Gapdh (F) ACCACAGTCCATGCCATCAC
Gapdh (R) TCCACCACCCTGTTGCTGTA
Villin (F) AGGAAGGAGGAGCACCTGTC
Villin (R) GGACAGCCAGAGAGCTTCAA
Real-time PCR quantification was performed using SYBR GreenERTM qPCR
supermix for ABI PRISM Instrument (Life Technologies, Grand Island, NY) according
to manufacturer’s instructions. Samples were run at the following conditions: 95C for 15
min, 40 cycles of 92C for 30 sec, 60C for 30 sec, 68C for 1 min followed by a
dissociation step. The relative amounts of mRNAs in each sample were normalized to
Villin or Gapdh for intestine samples or Gapdh values for liver, kidney samples to control
for quality of the mRNA. Comparative CT (ddCt) method was used to determine
quantitative PCR values.

Dexamethasone Pharmacokinetics
Dexamethasone administered in drinking water
8-10-week-old C57BL/6 VD3 Sufficient and VD3 deficient, male (n=8-13) and
female (n=5) mice were treated with the discontinuous DEX regimen as described in
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(Ramsey et al., 2015). 8 mg/L of dexamethasone sodium phosphate (Fresenius kabi LLC,
Lake Zurich, IL, USA) is given in drinking water for 3.5 days followed by OFF
dexamethasone but 600 mg/L of Sulfamethoxazole (Aurobindo Pharma Inc, Dayton, NJ,
USA) and 120 mg/L of trimethoprim (Aurobindo Pharma Inc, Dayton, NJ, USA) for the
next 3.5 days. 1 g/L of tetracycline (Sigma-Aldrich Inc, St. Louis, MO, USA) was added
during both phases. Assuming that mice drink 5 mL of water per day, the dose they
receive would be 1.6-2 mg/kg/day (Ramsey et al., 2015). This discontinuous DEX
ON/OFF schedule is then repeated with blood samples that were collected on day 0
(basal), and after each pulse of DEX i.e., day 3.5, 10.5 and 17.5 during the discontinuous
DEX treatment (Figure 3-2). Blood was centrifuged at 10000 rpm for 2 minutes and
plasma was stored on dry ice. At the end of in vivo procedures, all plasma samples were
transferred from dry ice and stored at –80C until analysis. DEX plasma concentrations
were measured using liquid chromatography with tandem mass spectrometric detection
(Ramsey et al., 2015).
Single oral dexamethasone gavage
The dosing and sampling scheme to assess DEX PK in mice after a single oral
dose were performed as previously described (J. Li et al., 2018). Briefly, 14-week-old
C57BL/6 VD3 sufficient and deficient male (n=5) and female (n=5) mice were given 2
mg/kg dexamethasone sodium phosphate dissolved in 0.5% hydroxypropylmethylcellulose (HPMC) and 1% Tween 80 by oral gavage. Blood was collected via
saphenous/retro-orbital vein at time points: 0.25, 0.75, 0.5, 1, 1.5, 2, 4, 8, 16 hours after
treatment (Figure 3-3). Samples were spun at 10000 rpm for 2 minutes for plasma
separation and stored at -80C until further analysis. DEX plasma concentrations were
measured using liquid chromatography with tandem mass spectrometric detection
(Ramsey et al., 2015).

Dasatinib Pharmacokinetics
The total plasma pharmacokinetics of dasatinib in C57BL/6 VD3 sufficient and
deficient mice were assessed after single oral gavage of 10 mg/kg of dasatinib free base
equivalents (St. Jude Compound Management, SJ000518976-9, LC Labs, D-3307, Lot
BDS-106, purity > 99%) was dissolved in 80mMol/L sodium citrate buffer pH 3.1 for a
total Dasatinib concentration of 1 mg/mL for a 10 mL/kg gavage volume. Mice were
grouped by vitamin D status and sex and studied at 8 and 10 weeks of age. Survival
saphenous and facial bleeding of mice was conducted using IACUC-approved methods at
0.125, 0.25, 0.5, 1, 2, 4, 8, 16 and 24 hr. post dose, with 3 mice per time point (Figure
3-4). Each mouse was sampled 3 times on 2 separate occasions of dasatinib dosing.
Blood was collected into a Sarstedt Minivette POCT 50 L K3 EDTA capillary device,
dispensed into a microtube and vortexed to mix the anticoagulant. The tubes were then
immediately centrifuged to plasma and stored on dry ice for the remainder of the study.
At the end of the in vivo procedures, plasma samples were transferred from dry ice and
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Figure 3-2. Experimental design for pharmacokinetics of DEX using
discontinuous DEX regimen in drinking water.
Data source: Ramsey, L. B., Janke, L. J., Payton, M. A., Cai, X., Paugh, S. W., Karol, S.
E., . . . Relling, M. V. (2015). Antileukemic Efficacy of Continuous vs Discontinuous
Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia. PLoS One, 10(8),
e0135134. doi:10.1371/journal.pone.0135134

Figure 3-3. Experimental design for pharmacokinetics of DEX post oral DEX
gavage (2 mg/kg).
Data source: Li, J., Chen, R., Yao, Q. Y., Liu, S. J., Tian, X. Y., Hao, C. Y., . . . Zhou, T.
Y. (2018). Time-dependent pharmacokinetics of dexamethasone and its efficacy in
human breast cancer xenograft mice: a semi-mechanism-based
pharmacokinetic/pharmacodynamic model. Acta Pharmacol Sin, 39(3), 472-481.
doi:10.1038/aps.2017.153
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Figure 3-4. Experimental design for pharmacokinetics of dasatinib post oral
dasatinib gavage (10 mg/kg).
Data source: Furmanski, B. D., Hu, S., Fujita, K. I., Li, L., Gibson, A. A., Janke, L. J., . .
. Baker, S. D. (2013). Contribution of ABCC4-mediated gastric transport to the
absorption and efficacy of dasatinib. Clin Cancer Res, 19(16), 4359-4370.
doi:10.1158/1078-0432.CCR-13-0980
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placed at -80C until analysis. Dasatinib bioanalysis and pharmacokinetic analysis (see
below) were performed by Preclinical Pharmacokinetic Shared Resource at St. Jude
Children’s Hospital and described in supplementary methods.
Dasatinib bioanalysis
Total plasma Dasatinib concentrations were assessed using a sensitive and
specific liquid chromatography, tandem mass spectrometry assay. Dasatinib stock
solutions were prepared in acetonitrile and used to spike matrix calibrators and quality
controls. Protein precipitation was performed using a 1:4 ration of plasma to 15 ng/mL
erlotinib HCl (St. Jude Compound Management, S00004053, Inventory ID:
SJCH0042996, Purity > 95%) in methanol as an internal standard. A 3L aliquot of the
extracted supernatant was injected onto a Shimadzu LC-20ADXR high performance
liquid chromatography system via a LEAP CTC PAL autosampler. The LC separation
was performed using a Phenomenex Kinetex 2.6 um EVO C18 (100A, 50 x 2.1 mm)
maintained at 50 C with gradient elution at a flow rate of 0.5 mL/min. The binary mobile
phase gradient began with a linear increase to 100% B in 4.0 minutes. The column was
then rinsed for 2.0 minutes at 100% B and then equilibrated at the initial conditions for
two minutes for a total run time of eight minutes. Under these conditions, the analyte and
IS eluted at 1.81 and 2.21 minutes, respectively. Analyte and IS were detected with
tandem mass spectrometry using a SCIEX API 5500 Q-TRAP in the positive ESI mode
with monitoring of the following mass transitions: Dasatinib 488.20 -> 401.00, erlotinib
HCl 394.20 -> 250.10.
The experimental bioanalytical runs were all found to be acceptable for the
purpose of a singlicate non-GLP, preclinical PK assessment. A linear model (1/X2
weighting) fit the calibrators across the 1.00 to 500 ng/mL range, with a correlation
coefficient ® of >= 0.9058. The lower limit of quantification (LLOQ), defined as a peak
area signal-to-noise ratio of 5 or greater verses a matric blank with IS, was 1.00 ng/mL.
The intra-run precision and accuracy was < 11.6% CV and 90.6%to 107% respectively.
Pharmacokinetic analysis
Plasma concentration-time (Ct) data in ng/mL for dasatinib were grouped by
individual mouse, Vitamin D status, sex, and age, and were analyzed using nonlinear
mixed effect (NLME) modeling as implemented in Monolix version 2018R1 (Lixoft
SAS, Antony, France). Briefly, parameters and the Fisher Information Matrix (FIM) were
estimated using the stochastic approximation expectation maximization (SAEM)
algorithm, and the final log-likelihood estimated with importance sampling, all using the
default Monolix initial settings, except that 1000 iterations were permitted for estimation
of FIM using stochastic approximation. A variety of models were fit to the dasatinib Ct
data, parameterized using apparent clearances, volumes of distribution, and absorption
rate constant as needed. These models were assessed for goodness of fit using the -2-log
likelihood (-2LL) value, Akaike and Bayesian Information Criterion (AIC, BIC), visual
predictive checks, plots of model individual and population predicted versus observed
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data, residual plots, and the standard error of parameter estimates. A log-normal interindividual and inter-occasion parameter distribution was assumed on selected supported
parameters, with both on- and off-diagonal elements of parameter covariance matrices
tested. Additive and/or proportional error models were tested and implemented as
supported. Beal’s M3 method was used to handle any data that were below the LLOQ or
above the upper limit of the assay range. The grouping levels were tested as categorical
covariates on supported PK parameters, primarily the apparent oral clearance (Cl). A
covariate effect was considered significant if its addition reduced the -2LL by at least
3.84 units (P < 0.05, based on the χ2 test for the difference in the -2LL between two
hierarchical models that differ by 1 degree of freedom). Additionally, Wald test P values
were outputted for each covariate effect by the Monolix software.

Survival Study
Murine BCR-ABL Arf-/- Luc+ ALL cells were created by Dr. Charles Sherr (St.
Jude Children’s Research Hospital) and provided by Dr. Mary Relling (St. Jude
Children’s Research Hospital). Cells were cultured previously as described (Ramsey et
al., 2014). C57BL/6 VD3 sufficient (n=24) and deficient (n=22) male mice (8-18 wk of
age) were injected with 2,000 BCR-ABL Arf-/- Luc+ ALL cells retro-orbitally on day
zero. Body weights were not significantly different at the start of the study (day 0).
Starting on day 4, mice were kept ON the discontinuous DEX dosing regimen (described
above) where DEX was supplied in drinking water for 3.5 days, and then removed for the
next 3.5 days, and this discontinuous DEX ON/OFF schedule was repeated until the
animals died from leukemia (Figure 3-5). Xenogen IVIS-200 (Caliper Life Sciences,
Hopkinton, MA) was used to acquire bioluminescent images 5 minutes post-intra
peritoneal injection of 200 L of 100 mg/kg D-Luciferin (Caliper Life Sciences,
Hopkinton, MA). Mice were anaesthetized with isoflurane during this procedure. The
bioluminescent signal (photons/s) from a fixed region of interest (ROI) is used to monitor
the disease progression twice every week. Images acquired here were analyzed using
Living Image 3.1 software (Caliper Life Sciences), where whole body luciferase flux
measurements (photons/s) was quantified as disease burden. Euthanasia was performed
when the animal reached moribund stage which was determined based on hind limb
paralysis, scruffy coat, lethargy or an inability to obtain food or water. We repeated the
survival study with DEX treatment by employing pups from pregnant females placed on
VD3 sufficient (n=13) and deficient (n=10) diets and observed similar effect that VD3
deficient mice with DEX treatment survived better than VD3 sufficient mice (data not
included).

Data Analysis
Unpaired t-test or Mann-Whitney non-parametric tests were used to determine the
significance in gene expression assays. Survival data was analyzed using Kaplan Meier
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Figure 3-5. Experimental design for survival of mice from BCR-ABL ALL placed
on discontinuous DEX regimen in drinking water.
Data source: Ramsey, L. B., Janke, L. J., Payton, M. A., Cai, X., Paugh, S. W., Karol, S.
E., . . . Relling, M. V. (2015). Antileukemic Efficacy of Continuous vs Discontinuous
Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia. PLoS One, 10(8),
e0135134. doi:10.1371/journal.pone.0135134
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survival analysis and Gehan-Breslow-Wilcoxin test was used to determine significance.
Significance is calculated at p<0.05 and the Grubb’s test on GraphPad QuickCals was
used to remove any outliers.

Results

Impact of Vitamin D Deficiency on Murine Duodenum Cyp3a and Transporter
mRNA Expression
Female C57BL/6 VD3 deficient mice had lower Cyp3a11 expression than VD3
sufficient mice, but the difference did not reach statistical significance (Figure 3-6B),
while no difference in Cyp3a11 mRNA expression was observed between male VD3
sufficient versus deficient mice (Figure 3-6A). To better predict the effect of VD3 levels
on human intestinal CYP3A4, we used a humanized transgenic mouse containing a
bacterial artificial chromosome with the complete human CYP3A4 gene including all of
its regulatory sequences (Cheung et al., 2006). Both mCyp3a11 and hCYP3A4 mRNA
expression trended lower in male 8-week old (but not 12 week) VD3 deficient versus
sufficient hCYP3A4-tg mice (Figure 3-6C). However, Cyp3a11 and hCYP3A4
expression were significantly lower in VD3 deficient female 12-week-old (but not 8
week) hCYP3A4-tg mice (Figure 3-6E, *p<0.05). Because ABC efflux transporters play
a major role in decreasing the oral bioavailability of DEX (Abcb1a/Mdr1a/Pglycoprotein) (Schinkel et al., 1995) and dasatinib (Mdr1a, Abcg2/Bcrp) (Hiwase et al.,
2008) we evaluated their expression and found their mRNAs were significantly higher in
the duodenums of VD3 deficient mice compared to sufficient mice (Figure 3-6C, F,
*p<0.05, **p<0.01). Vitamin D deficiency was confirmed in serum obtained from
terminal blood samples by analysis of 25-(OH) VD3 in the control, vitamin D deficient
mice (Table 3-1).

Cyp and Transporter Expression in Liver and Kidney of VD3-Sufficient and Deficient hCYP3A4-tg Mice
Because VDR can regulate expression of Cyp and transporters in other tissues
important for drug disposition, we examined expression of these detoxification genes in
kidneys and liver of mice with different vitamin D levels. In male mice, VD3 status had
no significant effect on hepatic Cyp3a, while in females hCYP3A4 expression trended
lower in VD3 deficient mice (Figure 3-7A, B). Renal expression of hCYP3A4 was
unchanged while Cyp24a1, a gene highly regulated by VDR (Kagi et al., 2018), was
lower in both male and female VD3 deficient mouse kidney (Figure 3-7A, *p<0.05). In
liver hepatic Mdr1a and Mrp4 were higher in male VD3 deficient mice (Figure 3-7C),
but significantly lower in female VD3 deficient mice (Figure 3-7D, *p<0.05, **p<0.01).
Renal Mdr1a and Mrp4 were lower in VD3 deficient mice, while in female mice VD3
levels had no significant effect on expression of renal efflux transporters (Figure 3-7D).
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Figure 3-6. Cyp and transporter gene expression in duodenum of VD3 sufficient
and deficient mice.
Notes: Influence of VD3 deficiency on intestinal Cyp3a11 expression in C57BL/6 (A)
male, n=3 and (B) female, n=3 mice. Comparative expression of intestinal Cyp3a11,
hCYP3A4, and drug efflux transporters in 8 and 12-week old hCYP3A4-tg (C, E) male
and (D, F) female mice. Data represents the results from 4-6 independent mice per group
in hCYP3A4-tg experiments and are expressed as mean (bars) + SE (error bars) fold
change in mRNA expression in deficient mice (green bar) relative to each mRNAs
expression in sufficient mice set as one (red bar). Villin was used as an internal control to
normalize the target gene expression data. Mann-Whitney nonparametric test on
GraphPad was used to determine significance between the groups (**p<0.01, *p<0.05).
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Table 3-1.
Serum 25(OH)VD3 levels in VD3-sufficient and -deficient mice
(Representative date).
Sample name

Gender

C57BL/6
C57BL/6
C57BL/6
hCYP3A4-tg
hCYP3A4-tg
hCYP3A4-tg
hCYP3A4-tg
C57BL/6
C57BL/6
C57BL/6
C57BL/6
C57BL/6
hCYP3A4-tg
hCYP3A4-tg
hCYP3A4-tg
hCYP3A4-tg

M
M
F
M
M
F
F
M
M
M
F
F
M
M
F
F

25-(OH)
VD3 (nmol/L)
246
403
454
297
171
221
187
6
17
18
7
12
15
15
17
12

Notes: M = Male, F= Female.
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Diet
VD3 sufficient
VD3 sufficient
VD3 sufficient
VD3 sufficient
VD3 sufficient
VD3 sufficient
VD3 sufficient
VD3 deficient
VD3 deficient
VD3 deficient
VD3 deficient
VD3 deficient
VD3 deficient
VD3 deficient
VD3 deficient
VD3 deficient

Figure 3-7. Cyp and transporter gene expression in liver and kidney of 12-week
old hCYP3A4 mice.
Notes: Comparative expression of hepatic and renal Cyps and efflux transporters in 12week old hCYP3A4-tg (A, C) male and (B, D) female mice. Data was analyzed and
graphed as described in Figure 3-6 legend.
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Plasma Dexamethasone Concentrations in VD3 Deficient versus Sufficient C57BL/6
Mice
Next, the effect of VD3 status on DEX systemic exposure was compared
following a discontinuous oral DEX regimen, similar to that used to treat pediatric ALL
patients, and that achieves plasma DEX concentrations (2.6 – 201.5 nM) in mice similar
to those achieved in pediatric patients on a discontinuous DEX regimen (Ramsey et al.,
2015). Male VD3 deficient mice had significantly (Figure 3-8A, *p<0.05) higher plasma
DEX levels compared to sufficient mice with a mean of 31.7 nM (n=8) and 12.43 nM
(n=11), respectively, on day 3.5, but no difference at later time points. A similar trend
was observed in females (Figure 3-8B) with the mean plasma DEX concentration only
different (63 nM in deficient versus 52 nM in sufficient mice) at an early time-point.
When we repeated the oral discontinuous DEX PK study in another 60 mice (15
per group) (Table 3-2) the DEX plasma concentrations were below the lower limit of
assay detection in a majority of both male (80%) and female (68%) VD3 sufficient mice
from Days 3.5 + 10.5, but was measurable in all female VD3 deficient mice and only
below the limit of quantification in 8% of VD3 deficient female mice. This suggested that
the higher intestinal Cyp3a in VD3 sufficient versus deficient mice was impacting DEX
systemic exposure, but only at the earliest exposure time points.
Because some of the variability in DEX concentrations between mice in all
groups could have resulted from the mice drinking variable amounts of water, DEX
pharmacokinetics was investigated following a single oral gavage of DEX (2 mg/kg) in
both male and female VD3 sufficient and VD3 deficient mice. There was no significant
difference between male or female VD3 sufficient versus deficient mice in their DEX
systemic concentration at any single time point or in DEX area under the concentration
curve (AUC) (Figure 3-9).

Tissue-specific Impact of Dexamethasone on Intestinal and Hepatic CYP Expression
in C57BL/6 VD3 Sufficient versus VD3 Deficient Mice
Why was there an apparent time-dependent effect of VD3 status on DEX PK in
mice (difference between groups seen only at early time points) on the discontinuous
DEX regimen? We hypothesized that VD3 regulated changes in intestinal Cyp3a
expression might be negated by prolonged treatment with DEX, that is also an inducer of
Cyp3a. Therefore, we determined whether there was any difference in DEX induction of
Cyp’s in intestine and liver of VD3 sufficient versus VD3deficient mice. Cyp expression
was analyzed in intestine and liver tissue from mice at day zero (no DEX) and on day 3.5
after a pulse of DEX using the oral discontinuous regimen. Duodenal Cyp3a11, Cyp3a13
and Cyp3a44 mRNAs were significantly induced (4-6-fold) (Figure 3-10A-C, *p<0.05)
by DEX only in the VD3 deficient mice. In the liver Cyp2b10 was induced at least 50fold in both VD3 sufficient and VD3 deficient male and female mice, with no significant
induction of hepatic Cyp3a’s in any mice (Figure 3-10D-G, *p<0.05). Thus, there were
divergent
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Figure 3-8. Plasma dexamethasone concentrations in C57BL/6 VD3 sufficient and
deficient mice on a discontinuous dexamethasone regimen.
Notes: Plasma DEX concentrations on days 0 (basal), and at the end of each pulse of
DEX i.e., days 3.5, 10.5 and 17.5 in (A) male (n=8-13/group), and (B) female (n=5) VD3
sufficient and VD3 deficient mice. The t-test on GraphPad was used to determine
significance between the groups (*p<0.05).

Table 3-2.

Repeat dexamethasone PK in drinking water.

Group
VD3 sufficient

Sex
M

Day 3.5
5 (10/15 BLQ)

Day 10.5
0 (10/10 BLQ)

Day 17.5
5

VD3 deficient

M

13 (2/15 BLQ)

10

5

VD3 sufficient

F

5 (10/15 BLQ)

3 (7/15 BLQ)

5

VD3 deficient

F

15

10

5

Notes: Number of samples in each group with dexamethasone plasma levels that were
measurable or below the lower limit of quantification (BLQ). M = Male, F= Female.
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Figure 3-9. Plasma DEX pharmacokinetics in VD3-sufficient and -deficient mice
after a single oral gavage of 2 mg/kg dexamethasone.
Notes: Plasma DEX concentrations in VD3-sufficient and -deficient 14-week (A) male
and (B) female mice. A t-test was used to determine the significance of differences
between VD3-sufficient and -deficient mice.
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Figure 3-10. Induction of duodenal and hepatic Cyps in VD3-deficient mice after
dexamethasone treatment.
Notes: Cyp3a mRNA expression was analyzed in VD3-sufficient and -deficient C57BL/6
male mice at time zero and following Dex in drinking water for 3.5 days, n=3-5 per
group: Intestinal (A) Cyp3a11, (B) Cyp3a13, (C) Cyp3a44, and hepatic Cyps in VD3sufficient and -deficient (D, F) male and (E, G) female mice (n=3-5 per group). Gapdh
was used as an internal control to normalize the target gene expression data. MannWhitney nonparametric test on GraphPad was used to determine significance between the
groups (**p<0.01, *p<0.05).
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effects of DEX on induction of Cyp3a’s and Cyp2b that was both tissue-specific: DEX
induction of Cyp3a was limited to VD3 deficient mice in intestine, and DEX induction of
Cyp2b was observed in liver. A model is proposed in the discussion to account for these
differential responses.

Dasatinib Pharmacokinetics (Oral Gavage) in C57BL/6 Mice
The plasma PK of dasatinib (a drug given throughout therapy to treat BCR-ABL+
acute lymphoblastic leukemias) was evaluated after two separate single oral gavage doses
of 10 mg/kg to determine the effects of VD3 status, sex and age (8 wk versus 10 wk) on
plasma PK using a nonlinear mixed effects PK modeling approach. Blood samples were
collected at 0.125, 0.25, 0.5, 1, 2, 4, 8, 16, 24 hr. post-dose with N=3 mice/group/time
point and assayed using LC-MS. There was no influence of VD3 status or sex or age on
oral dasatinib PK (Figure 3-11, *p<0.05). However, in males at both 8 and 10-weeks age
at the 0.25 hr time point, VD3 deficient mice had significantly higher plasma dasatinib
concentrations than VD3 sufficient mice (Figure 3-11A,C).
The oral dasatinib plasma PK in the studied mice was best described using a
linear, two-compartment, zero order absorption model, with proportional residual error.
Inter-individual variability upon apparent oral systemic clearance (Cl) and apparent
volume of distribution of the central compartment (V1) was supported, improved the
model fit and performance, as did the off-diagonal correlation between these two
parameters. This was defined as the Base model. Inter-occasion variability on either Cl or
V1 was not supported, resulted in model instability (failure of FIM convergence via
SAEM) and a poorer model fit. This prevented formal testing of age as a covariate but
implies that dasatinib PK is not significantly different between 8 and 10-week-old mice.
Vitamin D sufficiency and sex were then tested alone and combined as covariates on Cl
and were also found to be insignificant at the predefined p<0.05 threshold level. Overall,
the Base model without any covariates performed the best, and suggested no influence of
vitamin D status, sex, or age on oral dasatinib PK in mice.

Effect of Vitamin D Status on Anti-leukemic Efficacy of Dexamethasone
We recently found that VD3 deficient mice survived longer with BCR-ABL Arf-/ALL than sufficient mice in the absence of chemotherapy. We now compared survival
from BCR-ABL Arf-/- ALL between VD3-sufficient and -deficient mice with the oral
discontinuous DEX regimen. Leukemia was detected starting at day 19 in multiple VD3
sufficient mice but only in a few VD3 deficient mice (Figure 3-12). VD3 sufficient mice
began to succumb to tumor burden on day 26. VD3 deficient mice with DEX treatment
survived significantly (Figure 3-13, *p < 0.05) longer (median survival time 59 days)
compared to the DEX-treated VD3 sufficient mice (median survival time 36 days). The
proportion of total mice surviving BCR-ABL ALL at various time points (Table 3-3)
further showed that even with DEX therapy VD3 sufficient mice had poorer survival than
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Figure 3-11. Plasma dasatinib pharmacokinetics in VD3-sufficient and -deficient
mice after a single oral gavage of 10 mg/kg dasatinib.
Notes: Plasma dasatinib concentrations in VD3-sufficient and -deficient 8-week (A) male
and (B) female mice, and 10-week (C) male and (D) female mice. A t-test was used to
determine the significance of differences between VD3-sufficient and -deficient mice.
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Figure 3-12. Xenogen images tracking disease burden in VD3-sufficient and deficient male mice injected with BCR-ABL ALL.

Figure 3-13. Kaplan-Meier curves for the effect of VD3 sufficiency vs. VD3
deficiency on survival of mice from BCR-ABL Arf-/- leukemia.
Notes: Kaplan Meier survival curve plotted for male VD3 sufficient and VD3 deficient
mice with BCR-ABL Arf-/- leukemia and treated with a discontinuous dexamethasone
regimen. Prism (version 8) was used to plot and run statistical analysis. The GehanBreslow-Wilcoxon test was used to find differences between survival curves of VD3sufficient and -deficient groups (*p<0.05)
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Table 3-3.
Survival proportions of VD3-sufficient and -deficient mice treated
with dexamethasone during survival study from BCR-ABL.
Days survived VD3 sufficient
0
100.00
4

91.67

15

83.33

22

79.17

23

75.00

24

VD3 deficient
100.00
95.45

86.36

81.82

25

66.67

32

58.33

34

54.17

35

50.00

36

77.27

72.73

37

41.67

38

37.50

46

29.17

48

25.00

59.09

55

20.83

54.55

59

16.67

45.45

38

68.18

VD3 deficient mice. In sum, even with DEX chemotherapy, VD3 sufficient mice have a
worse survival outcome than VD3 deficient mice from BCR-ABL ALL (Figure 3-13).
No significant differences in serum chemistry except for lower high-density lipoprotein
(HDL) levels in VD3 deficient mice was observed (Figure 3-14).

Discussion
There are at least two clinical trials (Dana Farber and Children’s Hospital of LA)
(ClinicalTrials.gov Identifier number: NCT01574274 and NCT01317940, respectively)
administering vitamin D to insufficient and deficient pediatric acute lymphoblastic
leukemia patients to restore VD3 sufficiency. Since the biologically active metabolite of
VD3 (1,25(OH)2VD3) induces intestinal CYP3A4 in humans and Cyp3as in mice, and
since VD3 supplementation can alter the pharmacokinetics of orally administered
CYP3A4 substrates such as atorvastatin (Schwartz, 2009), we hypothesized that Cyp3as
might be higher in the intestine of VD3 sufficient versus VD3 deficient mice and that
could lead to increased metabolism, decreased systemic exposure, and decreased antileukemic efficacy of the orally administered chemotherapies. Because DEX and dasatinib
are majorly metabolized by CYP3A4 in humans (Christopher et al., 2008) (Gentile, 1996)
and are orally administered to patients orally during ALL therapy (Mitchell et al., 2005)
(Foa et al., 2011), this study sought to determine whether there might be unanticipated
vitamin D3 interactions with these orally administered CYP3A metabolized ALL
therapies.
In the C57BL/6J mouse model, the effect of VD3 levels was intestinal specific VD3 sufficient female mice had higher levels of intestinal Cyp3a11 compared to VD3
deficient mice while hepatic Cyp3a11 remained unchanged. This result is relevant to
humans because hCYP3A4 was also significantly lower in the intestine of the VD3
deficient humanized hCYP3A4-transgenic mouse. Consistent with lower intestinal Cyp3a
in VD3 deficient female mice we found serum concentrations of DEX administered by a
discontinuous oral regimen were transiently higher at the earliest, but not later times of
DEX therapy in these deficient mice. In contrast, when DEX was administered orally as a
single oral bolus dose, there was no significant difference in the DEX AUC between the
VD3 sufficient and deficient mice. It is possible that there was no difference in DEX
AUC following the single oral DEX gavage because the gut concentration (Cgut)
achieved ~200 µM (2 mg/kg into a gastric volume of 300 - 400 µL) might saturate Cyp3a
(assuming mouse Cyp3a is similar to CYP3A4’s Km of ~25 µM for 6- and 6hydroxydexamethasone formation) (Gentile, 1996). In contrast, mouse intestinal Cyp3a
would readily metabolize DEX from the drinking water assuming the DEX Cgut is ~7.6 –
10.1 µM at any time-point (assume drinking ~200 - 400 µl / hr). Similar to the findings
with dexamethasone, there was no influence of VD3 status on oral dasatinib PK.
While we chose to test the effect of VD3 levels on dexamethasone systemic
exposure because it is an orally administered anti-leukemic therapy, we would not a
priori have predicted that intestinal dexamethasone CYP3A-mediated metabolism would
be affected by VD3 levels for several reasons (Figure 3-15). First, DEX has a
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Figure 3-14. Serum chemistry of VD3-sufficient and -deficient mice.

Figure 3-15. Cartoon depicting dexamethasone and dasatinib metabolism and
efflux transport in intestine and liver.
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relatively high oral bioavailability in health individuals (76% and 81% (Loew, Schuster,
& Graul, 1986)). Hence, even though DEX e can be metabolized by intestinal tissue
(Siebe et al., 1993), CYP3A-mediated DEX first-pass metabolism in the gut is probably
minimal. Second, the magnitude of DEX drug-drug interactions with CYP3A inducers
and inhibitors (low-modest) supports this conclusion. Third, DEX is known to be
primarily cleared by hepatic pathways (Gentile, 1996) undergoing extensive CYP3A4
dependent hepatic metabolism in vivo and in vitro (Tomlinson et al., 1997), and there
was no effect of VD3 status on mouse hepatic Cyp3as consistent with the low levels of
VDR in hepatocytes compared to intestine (Gascon-Barre et al., 2003). Hence, it was not
clear that vitamin D induced variation in intestinal CYP3A4 expression would impact
oral DEX systemic exposure.
We chose to test the effect of VD3 levels on dasatinib pharmacokinetics because
this CYP3A substrate is given orally throughout therapy for BCR-ABL ALL. We would
have predicted that dasatinib oral bioavailability might be affected by VD3 levels (Figure
3-15). Dasatinib is rapidly absorbed from the gastrointestinal tract after oral dosing, with
the Cmax reached within 0.6 to 2 h. Bioavailability of dasatinib is quite variable with one
study showing 45-51% bioavailability (Luo et al., 2006) and other indicating 17% in
mice (Kamath, Wang, Lee, & Marathe, 2008). Using bile duct cannulated rats, the
percentage of unchanged drug in the gastrointestinal tract was 33% suggesting 67% was
absorbed. However, the oral bioavailability in these rats was 27%, which means 63% of
drug did not reach the systemic circulation, possibly due to pre-systemic metabolism.
Moreover, at least 40% of the total drug (or 60% of absorbed drug) might undergo
hepatic metabolism. Dasatinib is primarily metabolized by CYP3A4. How much does
intestinal CYP3A4 contribute to dasatinib metabolism? On the one hand coadministration of dasatinib with grapefruit juice is contraindicated (Squibb, 2006)
suggesting there is intestinal CYP3A4 metabolism. Moreover, the magnitude of reported
interaction with CYP3A inducers and inhibitors (large) supports the assumption of first
pass effect at both intestine and liver. However, it should also be considered that
CYP3A4-mediated dasatinib metabolism generates CYP3A4 mechanism-based
inactivators with a K(I) = 6.3 microM and K(inact) = 0.034 min (-1) (X. Li et al., 2009).
In our study dasatinib was dosed at 10 mg/kg, the calculated Cgut is 1.5 mM, and the
Cmax achieved was 2 µM (0.002 mM). Hence, it is possible that intestinal CYP3A4
undergoes mechanism-based inhibition by CYP3A4-generated metabolites while hepatic
CYP3A4 might not.
Is there an intestinal drug efflux transporter-mediated Vitamin D3 interaction with
either dexamethasone or dasatinib? An additional variable affecting oral dexamethasone
intestinal absorption could be intestinal Pgp (Schinkel et al., 1995). We first
demonstrated that intestinal P-gp is highly inducible not only by drugs (Schuetz,
Wrighton, Safe, & Guzelian, 1986) but also by vitamin D exposure (Thummel et al.,
2001). Hence, in theory variable VD3 levels could influence intestinal Pgp expression and
contribute to variable DEX absorption and systemic exposure. Dasatinib is also a
substrate of Mdr1a and Bcrp that are present at significant levels on the apical membrane
of intestinal enterocytes and each has been shown to contribute to limiting dasatinib’s
oral bioavailability (Lagas et al., 2009) (Chen et al., 2009). Conversely, evidence that
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there was a significantly lower dasatinib AUC in Mrp4 KO versus WT mice supports
Mrp4 enhanced dasatinib gastric absorption of (Furmanski et al., 2013). However, only
Mdr1a has been shown to be induced in enterocytes treated with vitamin D (Thummel et
al., 2001). However, not only did our study find no effect of VD3 levels in mice on
dasatinib’s AUC, nor any chronic effect on DEX systemic exposure, in fact the
expression of Mdr1a mRNA was actually higher in the intestines of VD3 deficient versus
sufficient mice, a paradoxical finding that others have also reported (Quach et al., 2018).
It is also possible that the paradoxical decrease in intestinal drug efflux
transporters for dexamethasone (Pgp, Bcrp) and dasatinib (Pgp) in VD3 Sufficient mice
(Figure 3-15) negated the increased intestinal Cyp3a in these same mice. VD3 deficient
mice had significantly lower intestinal Cyp3a expression, but significantly higher Mdr1a
levels. The combined opposing effects of metabolism and efflux transport on
dexamethasone and dasatinib in this model may have ultimately erased any individual
effect of VD3 on their metabolism or transport.
Why was DEX apparently more rapidly metabolized in VD3 deficient versus
sufficient male only at only the earliest measured time-point in mice given an oral
discontinuous dexamethasone regimen? We hypothesized that because DEX over time is
inducing intestinal Cyp3a only in the VD3 deficient mice this is negating the difference in
intestinal Cyp3a expression seen between VD3 deficient versus sufficient mice. The
inability to induce Cyp3a in VD3 in sufficient mice was not because some theoretical
maximum intestinal Cyp3a expression level has already been achieved in VD3 sufficient
mice because the threshold cycle (Ct value) for Cyp3a amplification was lower in VD3
deficient mice treated with DEX then in vitamin D sufficient mice with or without DEX
(i.e., the relative expression level of Cyp3a in the DEX induced VD3 deficient mice was
higher than the Cyp3a level in sufficient mice). Indeed, the selective DEX induction of
intestinal Cyp3a in VD3 deficient mice, but not sufficient mice (Figure 3-10), suggests
there is competition of VDR and PXR at the VDRE/PXRE binding sites in the Cyp3a
promoter. VDR/NR1I1 and PXR/NR1I2, both members of the NR1I family of nuclear
hormone receptors, share common DNA binding elements (Reschly & Krasowski, 2006).
We previously showed that VDR-RXR and PXR-RXR heterodimers bind to the identical
DNA elements in the Cyp3a promoter (Thummel et al., 2001). Moreover, there is
precedence for VDR-RXR and PXR-RXR heterodimers competing at common binding
elements because PXR bound by the potent ligand rifampin was previously shown to
inhibit VD3-ligand activated VDR binding to the CYP24 promoter in intestinal cells (C.
Zhou et al., 2006). Results from this study suggest that in sufficient mice VD3 activated
VDR-RXR bound to the Cyp3a VDRE/PXRE is preventing DEX (a relatively weak PXR
agonist (Kd~30 µM))-activated PXR-RXR from displacing VDR from the VDRE/PXRE
binding site (Figure 3-16). Conversely, in VD3 deficient mice the VDRE/PXRE is
unoccupied by VDR because the VD3 ligand level is insufficient to ligand activate DNA
binding, so the DEX -activated PXR-RXR can readily bind to and activate the Cyp3a
promoter (Figure 3-16).
Tissue-specific DEX induction of Cyp3a in intestine but not liver, but DEX
induction of Cyp2b in liver, suggests compartment specific induction of these Cyps
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Figure 3-16. Cartoon depicting hypothesis that dexamethasone-activated PXR can
induce Cyp3a in VD3 deficient mice, but not in VD3-sufficient mice where
1,25(OH)2D3-activated VDR blocks DEX-PXR induction.
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by PXR and the glucocorticoid receptor (Figure 3-17). The dose response curves for
glucocorticoid activation of GR versus PXR are strikingly different (Figure 3-17). GR is
ligand activated at nM concentration of glucocorticoids and makes physiological sense as
these steroids need to be maintained within a strict homeostatic range. In contrast, the
ED50 for PXR activation by glucocorticoids is approximately 30 µM (Kliewer et al.,
1998). Indeed, PXR requires stress/pathological levels and higher levels of
glucocorticoids to be activated and then to induce Cyp3a and other detoxification
pathways. If PXR were activated by glucocorticoids at nanomolar concentrations this
would profoundly perturb endogenous glucocorticoid homeostasis. In contrast, Cyp2b is
transcriptionally activated by the glucocorticoid receptor (GR) and we previously showed
GR is required for DEX induction of Cyp2b in mice (Schuetz et al., 2000). Conversely,
glucocorticoid induction of Cyp3a occurs via PXR with no participation of, or
requirement for, GR (Schuetz et al., 2000). The observed systemic concentrations of
DEX (2.6 – 201.5 nM) in mice on the discontinuous regimen were in the nanomolar
range which would activate GR, but not PXR, in liver. Accordingly, only Cyp2b was
induced by DEX -activated GR in liver (Figure 3-17). However, the gut concentration of
orally administered DEX would readily activate intestinal PXR. Importantly, these results
are directly relevant to the pediatric ALL patients treated with DEX as the plasma
concentrations achieved with the oral discontinuous regimen in mice are similar to those
achieved in patients treated with conventional DEX therapy (Ramsey et al., 2014).
We recently found in a murine BCR-ABL ALL model VD3 sufficient mice died
earlier than VD3 deficient mice (Chapter 4). Given our finding that VD3 deficient mice
had higher systemic DEX exposure compared to sufficient mice during the first days of
discontinuous DEX treatment we might have expected DEX treatment to negate this VD3
deficient survival advantage. However, DEX treatment was unable to reverse the survival
advantage of VD3 deficient over deficient mice with ALL. It remains to be determined
whether the effects of VD3 on survival of mice from BCR-ABL ALL translate to humans.
The 5-year event free survival rates for pediatric ALL have almost reached 90%
(Strahlendorf, 2018). However, it is always important to consider whether a therapeutic
intervention –e.g., vitamin D3 to treat vitamin D deficiency, might cause an unexpected
negative side-effect – in this case an unfavorable CYP3A vitamin D3-mediated drug
interaction. Our results in mice suggest that vitamin D supplementation to vitamin D
insufficient/deficient patients will not affect systemic exposures of DEX or dasatinib. Our
results do suggest the intriguing possibility that whether a patient is VD3 sufficient versus
deficient may have an impact on the magnitude of CYP3A-mediated drug interaction
with CYP3A inducers (including DEX) for substrates that undergo significant first pass
intestinal metabolism (e.g., atorvastatin) (Schwartz, 2009).
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Figure 3-17. Differences in plasma and gut dexamethasone concentrations
following oral discontinuous regimen leads to tissue specific activation of GR and
PXR.
Data source: Kliewer, S. A., Moore, J. T., Wade, L., Staudinger, J. L., Watson, M. A.,
Jones, S. A., . . . Lehmann, J. M. (1998). An orphan nuclear receptor
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CHAPTER 4.

ROLE OF VITAMIN D IN BCR-ABL ARF-/- ACUTE
LYMPHOBLASTIC LEUKEMIA1

Introduction
Vitamin D deficiency affects an estimated 1 billion people in the world across all
ethnicities and age groups (Boscoe & Schymura, 2006; Holick, 2007; Holick et al.,
2011). VDD is an independent risk factor for mortality in the general population
(Melamed, Michos, Post, & Astor, 2008) and almost 60% of children with malignant
diseases have suboptimal vitamin D levels (Sinha, Avery, Turner, Bailey, & Cheetham,
2011). VDD is not limited to developing countries, a recent study found that among 45
people tested in Memphis, TN for vitamin A and vitamin D levels, only two individuals
had sufficient levels of both vitamins (B. G. Jones et al., 2016).
Vitamin D is a fat-soluble vitamin that not only regulates calcium absorption and
bone metabolism, but can also regulate cell proliferation, differentiation and the immune
response. The biologically active form of Vitamin D, 1, 25(OH)2VD3, binds to the
vitamin D receptor (VDR) that heterodimerizes with the retinoid X receptor (RXR), and
that complex binds to VDR-RXR response elements in target genes to regulate
transcription. VDR is highly expressed in intestine, kidney and bone, but also in normal
and neoplastic hematopoietic cells and mesenchymal stem cells in bone marrow
(Haussler et al., 1998). 1, 25-(OH)2VD3, can modify embryonic hematopoietic stem and
progenitor cell production (Cortes et al., 2016). 1, 25(OH)2VD3 inhibits proliferation of
mouse and human myeloid leukemia cells (Tanaka et al., 1982) and stimulates myeloid
cell differentiation into mature macrophages. Indeed, mice with acute myeloid leukemia
when treated with analogs of 1, 25(OH)2VD3 survived longer than the untreated mice
(Abe et al., 1981). Moreover, vitamin D insufficiency/deficiency is associated with poor
clinical outcome and significantly worse progression free survival of patients from AML
(H. J. Lee et al., 2014), chronic lymphoid leukemia (Shanafelt et al., 2011), and nonHodgkin lymphoma (Drake et al., 2010) indicating the clinical significance of vitamin D
levels in patients with AML and CLL.
Acute lymphoblastic leukemia (ALL) is the most common form of childhood
cancer accounting for almost 80% of pediatric leukemias (Madhusoodhan, Carroll, &
Bhatla, 2016), and multiple reports suggest that a majority of leukemia patients are VD3
deficient at the time of diagnosis (Naz, Qureshi, Shamsi, & Mahboob, 2013; Sinha et al.,
2011). Accordingly, both Dana Farber (Identifier number: NCT01574274) and Children’s
Hospital of LA (Identifier number: NCT01317940) have ongoing pediatric ALL clinical
trials to monitor patients’ VD3 levels and to give supplementation to restore sufficiency.
However, it is not known how VD3 deficiency or supplementation might affect ALL

Modified from final submission with open access permission. Annu, K., Cline, C., Yasuda, K., Ganguly,
S., Pesch, A., Cooper, B., . . . Schuetz, E. G. (2020). Role of Vitamins A and D in BCR-ABL Arf(-/-) Acute
Lymphoblastic Leukemia. Sci Rep, 10(1), 2359. doi:10.1038/s41598-020-59101-4 (*Co-first author)
(Annu et al., 2020).
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progression or survival. Among the few reports of VD3 effects on the B-cell lineage of
ALL (B-ALL) (the most common form of pediatric ALL), there have been conflicting
results; one study concluded that VD3 had no effect on leukemia cell growth in
suspension cultures (Antony et al., 2012), while another study concluded that VD3
inhibited B-cell ALL growth in a clonigenic soft agar assay (Consolini et al., 2001).
Given the controversy in the literature, and the fact that a considerable number of ALL
patients are VD3 deficient and some of them are receiving VD3 supplementation, it is
important to test whether VD3 levels affect B-cell ALL cell growth, survival and
prognosis.
B-ALL is classified into different sub-types based on a number of chromosomal
abnormalities, and loss-of function or dominant-negative sequence mutations. Three-tofive percent of pediatric ALL cases and 25% of adult ALL cases, carry the translocation
between chromosomes 9 and 22 [t(9;22)] creating the BCR-ABL1 fusion gene (the
Philadelphia chromosome (Ph+)) (Williams & Sherr, 2008). At diagnosis around 67% of
pediatric Ph+ ALL patients also have Ink4-Arf deletion (Arf-/-) (hereafter called BCRABL ALL or BCR-ABL+ ALL) and approximately 80% have IKAROS (IKZF1)
alterations, which are considered hallmarks for high-risk B-ALL (Mullighan et al., 2008).
Therefore, we have tested the effects of vitamin D sufficiency versus deficiency on
survival in a murine BCR-ABL leukemia model and probed the mechanisms of their
differential effects.

Materials and Methods

Animals
C57BL/6, day 4-5 estrus pregnant (E4-5) female mice were obtained from
Jackson Laboratories (Bar Harbor, ME, USA). Animals arriving at the St. Jude
Children’s Research Hospital (SJCRH) animal facility were placed Purina Mills (Purina
Mills, St. Louis, MO, USA) diets – either control (cat. no. 5W9M contained 1.5 IU of
vitamin D), VDD (cat. no. 5W9X, contained 0 IU of vitamin D) were used for the
survival and other in vivo studies.
Pregnant dams were maintained on these diets from the time of arrival,
throughout the pregnancy, and after parturition. At weaning mouse pups were maintained
on their respective diets. We also used a different strategy to generate vitamin D
deficiency in mice by transitioning them to a VDD diet at weaning. This would eliminate
any potential effect of a vitamin D deficient diet on the status of any other systems in
pups derived from pregnant mom’s put on VDD diets at pregnancy day 5. Hence, mice in
a separate set of survival studies, were placed at weaning on a VDD diet (Harlan catalog
no. 5A69, 0 IU of vitamin D) and vitamin D sufficient control diet (catalog. no. 5BV8,
3.3 IU of vitamin D).
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Serum 25-(OH) VD3 levels were routinely measured from representative mice in
the VDD group (starting at 4 weeks of age) to determine vitamin D status. A level of 2050 ng/mL is considered vitamin D sufficient; 12-20 ng/mL is vitamin D insufficient, and
less than 12 ng/mL is vitamin D deficient. Sera were sent to Michigan State University
(Lansing, MI, USA) for 25-(OH) VD3 testing. Serum 25-(OH) VD3 levels were also
measured in mice at the terminal time point in the leukemia survival studies.

Ethical Approval Statement
Association for Assessment and Accreditation for Laboratory Animal Care
(AALAC) guidelines and Institutional Animal Care and Use Committee (IACUC)
approved protocols were followed for all the experimental procedures and housing of the
mice. All methods were carried out in accordance with the relevant guidelines and
regulations.

Leukemia and Bone Marrow Stroma Cells
Murine BCR-ABL+ Arf-/- cells tagged with luciferase (Luc+) or green
fluorescent protein (GFP+) (Williams, Roussel, & Sherr, 2006) created by Dr. Charles
Sherr’s lab and provided by Dr. Mary Relling’s lab, were cultured as previously
described (Ramsey et al., 2015). Human mesenchymal stromal cells (hMSCs, bone
marrow stroma) immortalized with telomerase (Mihara et al., 2003) and created by Dr.
Dario Campana’s lab, were provided by Dr. Jun Yang’s lab, and cultured as described
(Iwamoto, Mihara, Downing, Pui, & Campana, 2007).

BCR-ABL ALL Disease Generation and Monitoring
On day zero, 2,000 BCR-ABL Arf-/- Luc+ cells were injected retro-orbitally into
syngeneic, unconditioned 6-10-week-old mice, alternating injection order between cages
and groups. The first experiment was run with control male (M) (n=17), VDD M (n=23)
and control female (F) (n=14), VDD F (n=14) mice. Mice were anesthetized with
isoflurane and images using Xenogen IVIS-200 (Caliper Life Sciences, Hopkinton, MA)
were acquired post-intraperitoneal injection of 200 µL of 100mg/kg D-Luciferin (Caliper
Life Sciences, Hopkinton, MA). The bioluminescent signal (photons/s) was acquired
from a fixed region of interest (ROI) starting on day 8, repeating every 3-4 days to
monitor disease progression (Figure 4-1). Acquired images were analyzed with Living
Image 3.1 software (Caliper Life Sciences). BCR-ABL-Luciferase disease burden was
quantified from whole animal total luciferase flux measurements (photons/s) from the
images.
Moribund state of mice was determined based on hind limb paralysis, a scruffy
coat, lethargy, or an inability to obtain food or water. At this time before euthanasia,
blood was collected for the analysis of cholesterol, triglycerides, high-density lipoprotein
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Figure 4-1.

BCR-ABL ALL disease generation and monitoring in mice.
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(HDL) and low-density lipoprotein (LDL), white blood cell number, and serum for 25(OH) VD3. Spleen was harvested and bone marrow cells from femur were flushed using a
needle with either cell culture media or RNAlater (Invitrogen by ThermoFischer
Scientific, Vilnius, LT). The cells were transferred to a 1.5 mL eppendorf tube and
pelleted, the cell pellets were resuspended in 100 µL PBS, and transferred to white, clearbottomed 96-well plate (Costar, Corning Inc., Kennebunk, ME, USA) to which 100 µL of
Bright-Glo™ (Promega, Madison, WI, USA) was added. A standard curve with a range
of 3,000 to 2 million BCR-ABL cells was used in order to convert the luminescence
value into the number of BCR-ABL cells per well. Luminescence was measured using
the BioTek Synergy™ 4 Hybrid Microplate Reader.
A portion of spleen, hind limb was individually fixed in 10% formalin; 24 hours
later the tissues were transferred to Cal-Rite (Thermo Scientific, Pittsburgh, PA) for a
minimum of 48 hours. Tissues were embedded in paraffin, and 4 µm sections were cut
and stained with hematoxylin and eosin. Slides were evaluated by a pathologist to
determine the extent of leukemia burden, scoring the tissues on a 6- point scale from 0-5.
The entire experiment was repeated, and both studies were combined for the data analysis
with a total of control M (n=34), VDD M (n=34) and control F (n=27), VDD F (n=25)
mice.
To measure bone marrow vascularity and trabecular volume, the slides were
scanned using an Aperio ScanScope (Aperio Technologies, Vista, CA) with a 20X
objective. Measurements were performed using ImageScope software. The metaphyseal
region defined as beginning at the physis and ending 1mm distal to it; this marrow area
was outlined to obtain total metapyseal area. For measurement of bone marrow
vascularity all vascular lumens (sinusoids) were outlined within that area. Two types of
data calculated from these measurements, % vascular area (um2 vessel lumen/ um2
marrow), and length (um vessel/ um2 marrow). For trabecular volume, all trabeculae
were outlined within this area and the output was calculated as % trabecular area (um2
trabecular bone/ um2 marrow). Osteoblast and osteoclast numbers, as well as leukemia
burden, were evaluated semi-quantitatively by a veterinary pathologist (L.J.J.) using a 5point scale.

PCR Assays
PCR to determine gender of BCR-ABL ALL cells
The gender of the murine BCR-ABL+ Arf-/- cells was determined by PCR of
genomic DNA for the presence of X and Y-chromosome specific markers (McFarlane,
Truong, Palmer, & Wilhelm, 2013). DNA was amplified with the following primer pairs:
Sly/Xlr_F, 5ʹ-GATGATTTGAGTGGAAATGTGAGGTA-3ʹ;
Sly/Xlr-R, 5ʹ-CTTATGTTTATAGGCATGCACCATGTA-3ʹ and
Zfy_F, 5ʹ-GACT A GACATGTCTTAACATCTGTCC-3ʹ and
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Zfy_R, 5ʹ-CC T A TTGCATGGACTGCAGCTTATG-3ʹ and amplification conditions
were as described (McFarlane et al., 2013).
PCR to detect VDR mRNA
The expression of VDR in BCR-ABL+ Arf-/- and LS180 cells was determined by
PCR. DNA was amplified using the following primer pairs:
mVDR-F, CTCCTCGATGCCCACCACAAGACCTACG;
mVDR-R, GTGGGGCAGCATGGAGAGCGGAGACAG;
hVDR-F, CGGCCGGACCAGAAGCCTTT;
hVDR-R, CGGGGCACGTTCCGGTCAAA;
GAPDH-F, ACCACAGTCCATGCCATCAC;
GAPDH-R, TCCACCACCCTGTTGCTGTA.
Promega PCR master mix (catalog number M7505), and amplification conditions
are as described below: Denaturation at 95C for 2 min; 34 cycles (mVDR) or 40 cycles
(hVDR): denaturation at 95C for 30sec, annealing at 60C for 30 sec and extension at
72C for 30 sec; extension at 72C for 5 min; 4C hold. The product was mixed with 6x
DNA loading dye (Promega, WI, USA) and ran on a 2% agarose gel (used SYBR Safe
DNA gel stain) at 100 V for 90 minutes. Images were taken using Image Lab
SoftwareTM.

Analysis of in vivo Growth of Leukemic Burden
Change in leukemia burden with time was analyzed from the change in whole
body luminescence data. Luminescence data for every mouse was normalized with its
baseline luminescence value from day 8. Fold change in luminescence over baseline was
plotted against days, which was assumed to follow the exponential growth equation, Fold
change in luminescence=A e^(B*t), where, A is the intercept and B is the slope of the
exponential growth curve. Parameters A and B were estimated by fitting the fold change
in luminescence versus days for each mouse using Microsoft Excel-based trendline
analysis. Correlations were considered acceptable only if r2> 0.7. All the survivors were
removed from the analysis, as we do not expect to have increase/growth in leukemia
burden in these mice. Other filtration criteria were: 1) fold change in luminescence has to
be > 1, i.e., increase in luminescence over the baseline, 2) positive correlation of foldchange in luminescence with days, 3) there have to be at least three data points for the
assessment of correlation, and 4) since the same number of leukemic cells were injected
into the mouse, we expected to have no significant difference in intercept A and thus
outlier intercepts were removed from the analysis. After filtration of the data, individual
slopes (B) were computed for each mouse and compared between the groups, data
represented as median slope ± range and Mann-Whitney test at p< 0.05 was used to
analyze the significance.
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BCR-ABL ALL Viable Cell Number Assay
Luciferase-tagged BCR-ABL cells were plated at a density of 500 cells per well
on a 24 well plate and treated with either 1,25-(OH)2VD3 (50 or 100 nM) or ethanol
(vehicle) and the plates incubated at 37C 8% CO2. To select the concentration of 1,25(OH)2VD3 in cell culture, we first measured dose response effect on BCR-ABL ALL
viable cell number and found no effect with 1-10 nM, but equal effectiveness of 50-100
nM. Since the duration of our 1,25 (OH)2VD3 studies was routinely 48 hr (but as long as
96 hr), and the vitamin is not replenished after dosing at zero hr, and 1, 25-(OH)2VD3 has
a half-life of 15 hr, the effective concentration remaining at the end of a 48 hr experiment
following a 100 nM treatment is 25 nM.
In humans the bone marrow concentration of 1, 25-(OH)2VD3 is 500-fold higher
than the bone marrow plasma concentration (Blazsek et al., 1996). Since the plasma
concentration of 1,25(OH)2VD3 is 30 pg/ml (0.072 nM), the bone marrow stroma
concentration at 500-times that = 36 nM. Hence, 50-100 nM 1,25(OH)2VD3 was used.
To measure cell number, at the terminal time point for vehicle, 1,25(OH)2VD3 treated
wells, the entire contents of each well were transferred to a 1.5 mL eppendorf tube, the
cells were pelleted, resuspended in 100µL PBS, and transferred to white clear-bottomed
96-well plates (Costar Corning Inc., Kennebunk, ME, USA) and 100µL of Bright-Glo™
(Promega, Madison, WI, USA) was added. Luminescence was read using the BioTek
Synergy™ 4 Hybrid Microplate Reader. Standard curves were prepared in triplicate using
known numbers of Luc+ BCR-ABL cells, then the number of BCR-ABL cells in
experimental samples was determined by interpolation, and results plotted of average cell
number/treatment group or fold differences between vitamin treated and vehicle-treated
wells. Hence, the assay measures the difference in total number of cells between
treatment groups at a single time point. The assay measures number of viable (not dead
cells) because the assay depends on the number of cells that are viable and metabolically
active.

In vitro Homing Assay
hMSC (100,000/well) were plated onto the bottom of 24-well plates and treated
with ethanol vehicle or 100 nM 1,25(OH)2VD3 for 48 hours with half of the wells/group
treated with media lacking fetal bovine serum (FBS). Identical 24-well plates without
hMSC were prepared. Then 6.5mm Transwell Permeable Supports with a 3 µm
polycarbonate membrane (Costar Corning Inc., Kennebunk, ME, USA) were added to
each well and 1 million BCR-ABL luciferase(luc)+ cells in 100 µL of media was added
to top donor compartment and incubated at 8% CO2 for 24 hr. The bottom of each
transwell membrane (Figure 4-2) was then washed with media to collect any attached
cells. A cell scraper was used to remove all cells from the wells, which were pelleted and
resuspended in 100 µL PBS and 100 µL of Bright-Glo™ (Promega, Madison, WI).
The BioTek Synergy™ 4 Hybrid Microplate Reader was used to read the
luminescence on a white, clear-bottom 96 well plate (Costar, Corning Incorporated,
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Figure 4-2.

BCR-ABL cell migration in vitro using transwell membrane.
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Kennebunk, ME, USA). Luminescence from 3,000 - 2 million BCR-ABL luc+ cells was
used to generate a standard curve and the relative BCR-ABL cell number in the receiver
compartment was interpolated from the standard curve which was used to determine the
percentage of total cells that had migrated from the donor to the receiver compartment.

Real-Time PCR
A confluent layer of human bone marrow mesenchymal stem cells (hMSCs)
immortalized with telomerase (Mihara et al., 2003) were treated with vehicle or 100nM
1,25(OH)2VD3 for 48 or 72 hours. RNA was extracted using Trizol (Ambion Life
technologies, CA, USA or Thermo Fisher Scientific, CA, USA) and the Qiagen RNEasy
clean-up kit (Hilden, Germany). 500ng of RNA was used to create cDNA using the
ThermoScript™ RT-PCR System (Invitrogen ThermoFischer, CA, USA) that was then
diluted to a total volume of 60µL. Primers (Invitrogen, Carlsbad, CA) for amplification
of human CXCL12/SDF-1αwere (F) 5’-AGAACTGTTGGCAAGGTGACA-3’ and (R)
5’-CTGACATTCATATGGCTCTCATTC-3’; and for mouse CXCL12/ SDF-1αwere (F)
5’–CAGTGACGGTAAACCAGTCAGC- 3’ and (R) 5’–TGGCGATGTGGCTCTCG- 3’.
Samples were run at 95ᵒ for 15minutes and then 40 cycles of 92ᵒ for 30 seconds, 60ᵒ for
30 seconds, and 68ᵒ for 1 minute followed by a dissociation step for the real-time PCR.

CXCL12 ELISA Assay
The Quantikine ELISA Kit (R&D Systems, Minneapolis, MN, USA) for human
CXCL12/SDF-1α was used to assay both cell culture media and mouse serum according
to the manufacturer’s protocol. A standard curve was generated using the included
controls and used for comparison to a positive control as well as the unknown samples.
Cell culture media samples (n=3) from hMSCs in a 6-well dish were assayed undiluted
after 48-hour treatment with either ethanol or 100nM 1,25(OH)2VD3. Undiluted serums
from mice on either a VD3 sufficient (control) or VD3 deficient diet (VDD group; n=5 per
group) were also assayed using this approach. The BioTek Synergy™ 4 Hybrid
Microplate Reader was used to measure fluorescence at 450 nm and 540 nm. Final values
used for comparison were determined by subtracting the reading at 540 nm from the
reading at 450 nm; this step was designed to correct for optical imperfections in the plate.

Immunohistochemistry
VDD and control mice were perfused with 4% paraformaldehyde and the hind
limbs were fixed in 10% neutral buffered formalin, decalcified, embedded in paraffin,
sectioned (4 μm) and placed onto glass slides for staining. Antibodies for IHC were
obtained from Abcam and diluted in Phosphate Buffer Saline with 0.3% Triton X-100
(PBST). Slides containing either mouse tibia or mouse hind limb were deparaffinized and
antigens were retrieved using Target Retrieval solution pH 6.0 (Dako, Carpinteria CA,
USA) in a pressure cooker for 15 min. After retrieval, slides were rinsed with PBST,
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treated with 3% hydrogen peroxide, and blocked with Background Sniper (Biocare
Medical, Pacheco, CA, USA). Slides were incubated overnight at 4ᵒC with primary
specific antibodies (rabbit anti-collagen I, ab34710 (1:500) and rabbit anti-collagen V
(ab7046) (1:50), or the appropriate isotype control antibody, rinsed twice with PBST, and
incubated with the secondary antibody (Donkey anti-rabbit 568, ab10042) for 2 hr. Slides
were rinsed again in PBST and mounted using ProLong® Gold Antifade Mountant with
DAPI (Molecular Probes by Life TechnologiesTM, Eugene, OR, USA) and allowed to dry
overnight before viewing. Images were obtained (60X magnification) using the Marianas
Microscopy System (Intelligent Imaging Innovations).

Flow Cytometry
Age matched VD3 Sufficient and deficient mice are used for this assay. Isolation
of bone cells was performed as described in (Houlihan et al., 2012) with minor
modifications to the protocol. Cardiac puncture was performed to harvest blood which is
processed into serum and stored at -80C. This serum is used to measure the 25-(OH) VD3
levels in the mice. After euthanizing the mouse, both tibia and femur were dissected by
remove any adherent muscle tissue and cleaned carefully using Kimwipe to remove any
nonadherent tissue (Figure 4-3). Using a syringe filled with cold PBS, bone marrow is
flushed into a different test tube. The bones are placed in 30 mL of ice-cold PBS. The
bones were washed 3 times in fresh PBS by vigorous shaking. Using a sterile mortar and
pestle, the bones were crushed with one fracture per bone and using scissors to cut the
bone into small fragments. The bone fragments were washed 2-3 times using freshly
made 10 mL of HBSS+ solution. HBSS+ is made using Hank’s balanced salt solution
(HBSS) (Invitrogen, cat. no 14170112) as described in (Houlihan et al., 2012). Then the
bone fragments are placed into 50 mL conical tubes filled with 20 mL of preheated
DMEM with 0.2% collagenase and placed on a temperature regulated shaker at 37C for
1 hour at 110 r.p.m. Then, the solution is filtered using a 70 m cell strainer and placed
on ice. The fragments are placed into the mortar with HBSS+ solution and using pestle
gentle tapping is performed to liberate the bone cells into the solution. After performing
this step at least 6-7 times to obtain good yield, the suspension is centrifuged in a
precooled centrifuge at 280 g for 10 min at 4C. Supernatant was discarded carefully and
for red blood lysis to occur, the pellet was resuspended in 1 mL of ice-cold water for 6
sec. Immediately 1 mL of 2xPBS with 4% (v/v) FBS was added to stop the lysis and the
volume was made up to 15 mL using HBSS+. The solution is filtered through 70 m cell
strainer and spined once again for 5 minutes at 280 g in 4C. Supernatant was discarded
carefully, and the pellet was resuspended in 1 mL of HBSS+. This was later used for
staining of the bone cells. The antibodies used, concentrations and isotypes used to stain
the cells are shown below in the Table 4-1.

Data Analysis
Kaplan Meier curves were generated to compare survival data between the groups
and the Gehan-Breslow-Wilcoxon Test was used to determine significance. The Welch’s
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Figure 4-3.

Experimental design - bone/bone marrow cells isolation and staining

Table 4-1.
cytometry.

Antibodies used to stain bone and bone marrow cells for flow

Protein and
fluorochrome
CD31, FITC
CD51, PE
Sca-1, APC-Cy7
CD140a, PE-Cy7
CD140b, APC
CD45, BV605
Ter119, BV711
CD71, BV786

Company, Cat. no.
Biolegend, 102405
Biolegend, 104105
Biolegend, 108125
Biolegend, 135911
ThermoFisher
Scientific, 17-1402-82
Biolegend, 103139
Biolegend, 116233
BD Biosciences,
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Concentration

Isotype

0.5 mg/mL
0.2 mg/mL
0.2 mg/mL
0.2 mg/mL
0.2 mg/mL

Rat IgG2a, 
Rat IgG1, 
Rat IgG2a, 
Rat IgG2a, 
Rat IgG2a, 

0.2 mg/mL
0.2 mg/mL

Rat IgG2a, 
Rat IgG2b, 
Rat IgG2b, 

t-test was used to determine significant differences in ROI means between the groups.
Luciferase signals of blood, spleen, and bone marrow, and ELISA data were analyzed
using Mann-Whitney nonparametric test on GraphPad Prism versions 5 and 7. Blood
chemistry data were analyzed using 1way ANOVA with Tukey’s multiple comparison
test. Significance is calculated at p<0.05 and outliers were determined using Grubb’s test
on GraphPad QuickCalcs. Real-Time PCR data was analyzed using the ΔΔCt method.
Unpaired t-tests were used to determine significance in other assay’s comparing cells
treated with 1,25(OH)2VD3 or vehicle. Flow cytometry comparisons were done using
unpaired t-tests using GraphPad Prism software.

Results

Vitamin D Deficiency Improves Survival of Mice with BCR-ABL Arf-/- B-ALL
Progression of BCR-ABL Arf-/- luciferase tagged pre-B leukemia cells and
survival from disease were compared between vitamin D sufficient control mice and
VDD mice by Xenogen imaging of leukemic cells starting on day 8 in male and female
mice (Figures 4-4, 4-5). Leukemia was detected at day 8 in control male mice but was
not detected in the VDD male mice until day 10. Surprisingly, compared to VD3
sufficient (control) mice, VDD mice showed a slower tumor progression over time and
had lower average disease burden per mouse (Figure 4-6). Consequently, VDD mice
survived significantly longer (Figure 4-7, **p=0.003) than VD3 sufficient control mice.
This can also readily be seen by comparing the proportion of mice surviving on each day
after leukemia was administered (Table 4-2). For example, study 1 on Day 18 only 47%
of the control male mice versus 80.95% of the VDD male mice were surviving, hence the
median survival for the control male mice was 18 days versus 21 days for the VDD male
mice. Female mice inoculated with tumor cells had slow growth of disease and longer
median survival than males, so we determined the sex of the murine BCR-ABL leukemia
cells using a PCR assay to discriminate X and Y chromosome specific genes in the
leukemia cells. This PCR assay relies on Y chromosome specific Zfy amplification in
males, but is absent in females, and amplification of a 280 bp Y chromosome specific Sly
gene product in males, and a 480/685 bp X chromosome specific Xlr gene product in
females (McFarlane et al., 2013). The BCR-ABL cells were male as indicated by the Zfy
and Sly Y chromosomal PCR products (Figure 4-8).
Vitamin D deficiency was confirmed in serum obtained from terminal blood
samples by analysis of 25-(OH) VD3 in the control, VDD mice (Table 4-3). Complete
blood count (CBC) (Table 4-4) and serum chemistries (Table 4-5) were compared
between control, VDD mice with BCR-ABL ALL diseased and non-leukemic healthy
mice (no disease controls (ND)), Compared to leukemic control mice, leukemic male
mice deficient for vitamin D had decreased red blood cell number, hematocrit and
hemoglobin consistent with higher leukemic burden in these mice. Comparing serum
chemistries between the groups, the vitamin deficient males had elevated levels of HDL
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Figure 4-4.

BCR-ABL luc+ ALL disease burden in male mice.

Figure 4-5.

BCR-ABL luc+ ALL disease burden in female mice.
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Figure 4-6.
mice.

BCR-ABL ALL disease burden on day 17 in male control and VDD

Notes: The unpaired t-test with Welch’s correction was used to compare leukemia body
burden (***p=0.001)

Figure 4-7. Kaplan Meier survival curve of male VD3 sufficient (control) and VD3
deficient mice.
Notes: The Gehan-Breslow-Wilcoxon test was used to find differences between survival
curves of control and each vitamin deficient group (****p<0.000, **p<0.01)
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Table 4-2.

Survival proportions of control and vitamin D-deficient mice.
Days elapsed

Control

0
5
16
17
18
19
20
21
24
25
29

100

47.06
11.76
0.00

Vitamin D
deficient
100
95.24
85.71
80.95
71.43
61.90
42.86
33.33
9.52
0.00

Notes: Control = Vitamin D sufficient

Figure 4-8.

Determination of mouse gender using Sly/Xlr and Zfy PCR.

Notes: Genomic DNA from YY male and XY female mice were amplified with primers
for (A) Y chromosome Sly intron 8 and (B) X chromosome Xlr intron 6 and Y
chromosome Zfy.
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Table 4-3.

Serum 25-(OH) VD3 values across groups (Representative data).
Group

Gender

CON
CON
CON
CON
VDD
VDD
VDD
VDD

F
F
M
M
F
F
M
M

25-(OH) VD3
(ng/mL)
102.8
50.4
87.6
36.4
2.4
1.6
3.2
2.4

Notes: CON = VD3 sufficient, VDD = VD3 deficient, M = Male, F = Female.
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Table 4-4.
VD3-sufficient (control), -deficient (VDD) male (M) mice complete
blood count (CBC).
Cell type
WBC (X 103/uL)
Neutrophil (#)
Lymphocyte (#)
Monocyte (#)
Eosinophil (#)
Basophil (#)
Nucleated RBC (#)
Neutrophil (%)
Lymphocyte (%)
Monocyte (%)
Eosinophil (%)
Basophil (%)
Nucleated RBC (%)
Hematocrit (%)
RBC (X 106/uL)
Hemoglobin (g/dL)
Mean Corpuscular
Volume (fL)
Mean Corpuscular
Hemoglobin (pg)
Mean Corpuscular
Hemoglobin Conc
(g/dL)
Red Cell Distribution
Width (%)
RSD
Reticulocyte (#)
Reticulocyte (%)
Platelet (X 103/uL)
Mean Platelet
Volume (fL)
Platelet Distribution
Width
Plateletcrit

Control M
Average
S.D.
45.94
30.1
18.46
9.19
15.43
13.26
10.14
8.16
1.73
1.43
0.19
0.21
0
0
41.99
8.07
32.74
7.56
21.21
5.42
3.67
2.78
0.38
0.4
0
0
33.5
2.94
8.03
0.71
12.01
1.18

VDD M
Average S.D.
38.78
15.48
17.22
7.55
10.78
4.97
7.07
2.93
2.84
2.37
0.87
0.78
0
0
44.76
7.82
28.37
8.85
18.31
2.47
6.56
3.12
2
1.05
0
0
28
4.31
6.63
0.91
10.02
1.39

Control M ND
Average S.D.
2.55
2.19
0.39
0.32
1.97
1.71
0.19
0.17
0.01
0.01
0.01
0.01
0
0
15.22
0.51
76.98
0.74
7.1
0.62
0.45
0.46
0.26
0.37
0
0
31.6
1.41
7.89
0.45
12.05
0.49

VDD M ND
Average
S.D.
5.57
0.72
1.11
0.11
4
0.73
0.47
0.11
0.01
0.01
0
0
0
0
19.89
0.62
71.46
3.83
8.54
3.09
0.13
0.11
0
0
0
0
31.05
2.19
7.55
0.91
11.6
0.71

41.72

1.38

42.12

1.02

40.05

0.49

41.25

2.05

14.95

0.58

15.1

0.47

15.3

0.28

15.45

0.92

35.83

0.76

35.89

1.32

38.1

0.14

37.35

0.35

13.45

0.91

12.77

0.34

13.7

0.57

13.95

0.49

5.61
14.69
0.2
412.8

0.56
17.73
0.25
114.23

5.38
4.32
0.07
257.33

0.19
5.03
0.09
43.81

5.5
9.85
0.13
505.5

0.14
12.8
0.17
27.58

5.75
8.95
0.13
469.5

0.49
12.66
0.18
154.86

5.68

0.39

5.54

0.35

5

0

4.85

0.07

65.15

9.56

66.86

9.29

48.9

0.42

49.8

0.57

0.24

0.08

0.14

0.03

0.25

0.01

0.23

0.07

Notes: Control = VD3 sufficient, VDD = VD3 deficient, M = Male, ND = No disease,
S.D. = Standard deviation.
Red font indicates higher levels compared to control group; Green font indicates lower
levels compared to control group
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Table 4-5.
Parameter
Triglyceride
(mg/dl)
HDL (mg/dl)
LDL (mg/dl)
Cholesterol
(mg/dl)

VD3-sufficient and -deficient male mice serum chemistry.
Control M
Average S.D.

VDD M
Average S.D.

Control M ND
Average S.D.

VDD M ND
Average S.D.

52.99
47.24
9.15

15.89
12.71
1.99

44.63
58.46
18.31

13.17
10.49
16.24

66.15
87.15
8.45

3.04
6.58
0.49

39.15
45.25
4.10

17.61
42.78
3.25

102.82

27.20

116.00

16.24

139.50

3.54

73.00

70.71

Notes: Control = VD3 sufficient, VDD = VD3 deficient, M = male, ND = no disease, S.D.
= standard deviation, HDL = High-density lipoprotein, LDL = Low-density lipoprotein.
Red font indicates higher levels compared to control group.
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Body weights of animals on day 1 of experiments 1and 2 were compared. The mean body
weights (g) for male vitamin sufficient (21.58 + 1.95) versus. VDD (21.5 + 1.99) mice,
and female vitamin sufficient (17.83 + 0.99), VDD (17.09 + 1.35) mice were not different
from control. In addition, bone vascularity, trabecular volume, and osteoblast and
osteoclast numbers were evaluated on the same HE-stained longitudinal sections of tibia
and no significant differences between the control and VDD group were observed.

Bone Marrow and Spleen BCR-ABL Leukemia Burden is Lower in VDD Mice
Compared to Vitamin D Sufficient Mice
To further assess the relative leukemia burden at the primary sites of leukemia
replication such as bone marrow and spleen. We quantified the number of luciferasetagged BCR-ABL cells in the bone marrow (Figure 4-9A). In addition, a blind scoring of
the disease burden in H&E stained histological sections of the hind limb and spleen was
performed by the pathologist (Dr. Laura Janke, St. Jude Children’s Research Hospital)
(Figure 4-9B, 4-9C). Consistent with lower total leukemia body burden (Figure 4-6),
VDD male mice had lower levels of bone marrow, hind limb and spleen leukemia.

Mice Vitamin D Deficient for a Shorter Time Interval Still Show Increased Survival
from BCR-ABL ALL Compared to Vitamin D-Sufficient Mice
All of the mouse survival studies were performed on mice rendered vitamin
deficient by placing pregnant females on vitamin D deficient diets during pregnancy and
parturition and maintaining weaned pups on these deficient diets. We also used an
alternate strategy to generate vitamin D deficiency in a shorter time frame and compared
BCR-ABL ALL survival between vitamin D sufficient mice and mice rendered VDD by
placing them on a VDD diet at 4 weeks (weaning), using them after 10 weeks of age.
Despite the shorter duration of vitamin D deficiency, VDD mice still had prolonged
survival from BCR-ABL Arf-/- ALL (Figure 4-10).

1,25(OH)2VD3 Increases the Number of BCR-ABL Arf-/- ALL Cells Only When Cocultured with Bone Marrow Stromal Cells
To begin exploring the mechanism of how BCR-ABL+ ALL was proliferating
more rapidly in vitamin D sufficient versus deficient mice (Figures 4-4, 4-5, 4-6), we
examined the effect of 1, 25-(OH)2VD3 treatment on BCR-ABL Arf-/- leukemia cells.
Because mouse BCR-ABL+ Arf-/- leukemia cells, like human primary B-ALL cells
(Consolini et al., 2001), lack VDR (Figure 4-11) required for mediating the VD3 signal,
and because leukemic cells proliferate in the bone marrow, BCR-ABL+ B-ALL cells
were co-cultured with immortalized human mesenchymal stromal cells (hMSCs)
expressing VDR (Figure 4-11) that mimic a bone marrow micro-environment. There was
no effect of 1, 25(OH)2VD3 on number of viable BCR-ABL+ B-ALL cells grown without
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Figure 4-9.
mice.

Luminescence measure and leukemia score in control and VDD male

Notes: (A) Luminescence measure of BCR-ABL Luc+ Bone marrow disease burden in
male control and VDD mice, (B) Hind limb leukemia score in male control and VDD
mice, (C) Spleen leukemia score in male control and VDD mice.

Figure 4-10. Kaplan meier survival curves using male mice started on control
(vitamin D sufficient) and VDD diet beginning at weaning.
Notes: (A) Study 3 - Control (n=15) versus VDD (n=15), (B) Study 4- Control (n=15)
versus VDD (n=15), (C) Study 3 and 4 combined curves. Differences between survival
curves was determined using Gehan-Breslow-Wilcoxin test. The median survival for the
control mice vs. VDD mice was 26 versus 36 days (A) and 26 versus 30 days (B).
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Figure 4-11. Determination of VDR expression using PCR.
Notes: (A) Lane 1: M.W, Lane 2-6 showing GAPDH band at 500bp and lane 2-4
(positive control: mouse duodenum, kidney) mVDR band at 300bp, no band in lane 5-6
for mVDR in BCR-ABL ALL cells, (B) Lane 2-4 showing GAPDH band at 500bp and
lane 5 (positive control, LS180 cells) hVDR band at 190bp, lane 6: hMSCs treated with
ethanol no band of hVDR, lane 7: hMSCs treated with 1,25(OH)2VD3 a band of hVDR.
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hMSCs (p=0.5972); however, 1, 25(OH)2VD3 increased the number of BCR-ABL cells
(2.102 ± 0.415- fold higher, p=0.012)) (Figure 4-12) when co-cultured with hMSCs. This
result suggests that 1,25(OH)2VD3 is acting through the stroma to enhance BCR-ABL
ALL cell growth. In total, this result showed that 1, 25(OH)2VD3 enhances BCR-ABL
ALL cell number in vitro and this requires co-culture with bone marrow stroma.

1, 25(OH)2VD3 Increases BCR-ABL Cell Migration to hMSCs in Transwell Culture
Since the in vivo vitamin D sufficient (control) mice showed higher ALL disease
burden in the bone marrow, compared with the VDD mice (Figure 4-9) we next tested
whether this also reflected vitamin D increasing migration of the leukemic blasts to the
bone marrow stroma. An in vitro cell homing assay was used in which we measured the
percentage of BCR-ABL leukemia cells migrating from the donor chamber of a transwell
culture through a semi-permeable membrane to the bottom chamber containing media or
containing hMSC conditioned with or without 1,25(OH)2VD3 (Figure 4-13).
There was no effect of 1,25(OH)2VD3 on migration of ALL cells in the absence of
hMSCs. However, BCR-ABL ALL cells were stimulated to migrate to hMSCs and a
significantly greater percentage of BCR-ABL cells migrated to hMSCs conditioned for
48 hours with 100 nM 1, 25-(OH)2VD3 (Figure 4-13, **p=0.007). Fetal bovine serum
(FBS), which alone can also provide the media with factors required for BCR-ABL cell
migration, further increased the effect of 1, 25-(OH)2VD3 (p = 0.064). This result
demonstrates the ability of 1, 25-(OH)2VD3 to enhance BCR-ABL cell migration is not
intrinsic to the BCR-ABL blast, but rather, is due to VD3-initiated reprogramming of the
hMSCs to attract more BCR-ABL cells.

1,25(OH)2VD3 Increased CXCL12 mRNA and Protein Expression in hMSCs in vitro
and in Mouse Serum in vivo
CXCL12 (stromal cell-derived factor-1, Sdf-1) is a chemokine produced by
stromal cells, endothelial cells and osteoblasts, that plays an important role in normal Bcell lymphopoesis, cell trafficking and homing to the bone marrow (L. Ding & Morrison,
2013), and it has been shown to increase proliferation of primary pre-B-ALL (Mowafi et
al., 2008). Induction of CXCL12 mRNA (Figure 4-14) expression was higher in hMSCs
treated with VD3 for either 48 or 72 hours compared to control vehicle treated cells
(9.179 ± 2.415-fold (****p < 0.0001) and 10.320 ± 2.060-fold (***p = 0.0002) increases,
respectively.
Likewise, cell culture supernatants from hMSCs conditioned for 72 hours with
1,25-(OH)2VD3, had a 2-fold increase in secreted CXCL12 protein compared with
vehicle treated controls (Figure 4-15A, *p=0.029). There was a trend toward a higher
serum CXCL12 protein level in VD3 sufficient versus VD3 deficient mice (Figure
4-15B, p=0.095). However, we did not find a significant difference in the CXCR4 (the
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Figure 4-12. 1, 25(OH)2VD3 increases BCR-ABL proliferation in vitro.
Notes: The effect of 1,25(OH)2VD3 vs. vehicle treatment on growth of BCR-ABL ALL
cell number when cultured in the absence or presence of hMSC and plotted as fold
change relative to group control, n=3 per group. The unpaired t-test was used to compare
differences in BCR-ABL cell number.

Figure 4-13. Increased migration of BCR-ABL leukemia cells to VD3 treated bone
marrow stroma.
Notes: The percentage of the total number of BCR-ABL ALL Luc+ cells that migrated to
the bottom chamber was determined. The unpaired t-test was used to compare increase in
cell number (**p<0.01).
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Figure 4-14. Vitamin D induces CXCL12 mRNA in bone marrow stroma in vitro.
Notes: CXCL12 mRNA transcripts in hMSC cells treated with ethanol (EtOH) or 100 nM
1,25(OH)2VD3, n=8 or 10 per group. Unpaired t-test was used to determine significance
between the groups (***p<0.001, ****p<0.0001).

Figure 4-15. Vitamin D induces CXCL12 protein expression in bone marrow
stroma in vitro and in serum of mice in vivo.
Notes: CXCL12 protein expression in the media of hMSC cells treated with ethanol
(EtOH) or 100 nM 1,25(OH)2VD3, n=4 per group. CXCL12 protein expression in the
serum from VD3 sufficient (control) or VDD mice, n=5 per group. Mann-Whitney
nonparametric test on GraphPad was used to determine significance between the groups
(*p<0.05)
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CXCL12 receptor) expression in 1, 25-(OH)2VD3 treated versus ethanol treated BCRABL ALL cells (not shown). Hence, 1, 25-(OH)2VD3 reprograms the bone marrow
stroma to produce and secrete CXCL12 to attract leukemia cells.

CXCL12 Increases the Number of BCR-ABL Cells in Suspension Culture
To determine whether CXCL12 could directly affect BCR-ABL cells, we treated
cells in culture with CXCL12. Since VD3 stimulated hMSC cells produced 0.5 ng/ml of
CXCL12 (Figure 4-16), BCR-ABL cells in suspension culture, or co-cultured with
hMSCs, were treated with 0.5 ng/ml CXCL12 for 48 hours. CXCL12 produced a
significant increase (*p=0.04) in BCR-ABL cell number in cells in suspension culture,
but no further increase in the number of viable BCR-ABL cells co-cultured with hMSC.
This demonstrates that exogenous CXCL12 can directly stimulate growth of BCR-ABL
leukemia cells.

Vitamin D Plus ALL Reprograms the Bone Marrow Stroma
A growing body of literature demonstrates a role for VD3 in remodeling stroma
that can then affect cancer growth and chemotherapeutic response (Mowafi et al., 2008).
Similarly, the presence of leukemia in the bone marrow has been shown to transform the
bone marrow niche into a leukemia-permissive microenvironment causes reprogramming
(B. Kumar et al., 2018).
To test whether vitamin D remodels the extracellular matrix production by bone
marrow stroma, immunohistochemistry for type I and V collagen was performed on the
bone marrow of healthy vitamin D sufficient and deficient mice, as well as on those with
BCR-ABL ALL obtained at the time of sacrifice. Both type I and V collagen were
minimally detectable in the bone marrow of healthy mice, regardless of vitamin D levels,
but increased in the marrow of mice with ALL, but more frequently in the VD3 sufficient
(control) group (Figure 4-17). Hence, the presence of BCR-ABL together with vitamin D
is reprogramming the bone marrow stroma to increase production of type I and V
collagens.

Vitamin D Deficiency Alters the Number of CXCL12 Expressing Cell Types in Bone
Marrow and Bone
To evaluate if vitamin D deficiency had any effect on the bone marrow
microenvironment, we evaluated the abundance of different cells that express CXCL12 in
bone tissue and bone marrow. In vitro vitamin D induced CXCL12 expression in hMSCs,
but in vivo many other cells types such as endothelial cells, osteoblasts, perivascular
stromal cells and CXCL12 abundant reticular cells (CAR) also significantly express
CXCL12. We analyzed the percentage of these cell types by flow cytometry in vitamin D
deficient versus sufficient mouse bone and bone marrow tissues. We observed that, VD3
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Figure 4-16. CXCL12 increases proliferation of BCR-ABL ALL cells in suspension
culture.
Notes: Effect of CXCL12 treatment (48 hr) on BCR-ABL cell number in cells cultured
alone or with hMSCs, n=3 per group. The unpaired t-test was used to compare increase in
cell number (*p<0.05)

Figure 4-17. Effect of vitamin D and BCR-ABL leukemia on expression of type 1
and type V collagens in mouse bone marrow.
Notes: Fluorescent immunohistochemistry was performed on paraffin embedded mouse
tibias to examine the expression of collagens 1 and V in vivo. Collagens 1 and V both
show the highest expression in VD3 sufficient mice with ALL.
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deficient mice had lower percentage of CD31 negative cells (Figure 4-18) in the bone
marrow which consists of all the CXCL12 expressing cells except endothelial cells. The
percentage of CXCL12 expressing cell types PS stromal cells (PS), mesenchymal
stem cells (MSCs), osteoblasts and CAR cells in bone marrow was low in the bone
marrow of vitamin D deficient mice compared to the sufficient mice. We also observed a
significant effect of vitamin D deficiency in the bone tissue where CD31 negative cell
percentage was significantly low compared to sufficient mice (Figure 4-19). However,
PS, MSCs and osteoblasts, although they make up a very small percentage of CD31
negative cells, were significantly higher in VD3 deficient mice compared to sufficient
mice. But CARs are the most abundant CD31 negative cells making up to 25-30% of
CD31 negative cells and are significantly lower in VD3 deficient bones (Figure 4-19).

Discussion
Despite the high frequency of vitamin D deficiency in humans worldwide, this is
the first study to test and demonstrate that host deficiencies in vitamin D can affect
growth of BCR-ABL ALL Arf-/- leukemia and survival of mice from this disease. Our
study found that vitamin D sufficient mice had markedly accelerated disease progression
and decreased survival from BCR-ABL ALL compared to mice that were vitamin D
deficient. A similar effect of vitamin D deficiency on survival from BCR-ABL ALL was
seen regardless of whether mice were exposed to a VDD diet during gestation (Figure
4 -7) or started the diet at weaning (Figure 4-10), demonstrating the effect vitamin D
deficiency on BCR-ABL leukemogenesis in this mouse model does not require
deficiency during gestation.
Surprisingly, host VD3 sufficiency versus deficiency was detrimental to host
survival from BCR-ABL Arf-/- ALL. Importantly, 1,25 (OH)2VD3 had no effect on
growth of the leukemia cells in suspension culture but required co-culture with the bone
marrow stroma. This result is consistent with the apparent absence of the VDR in mouse
BCR-ABL+ ALL Arf-/- leukemia cells, and similarly its absence in human primary BALL cells (Consolini et al., 2001).
Our results also offer a cautionary reminder for the many studies that test the
effect of chemicals on leukemia cells grown in suspension culture, without co-culture of
bone marrow stromal cells, as these studies may miss important leukemia cell responses
that are only seen in a co-culture setting. Bone marrow stroma cells are known to form a
microenvironment not only conducive for leukemic cell growth, but that can also regulate
responsiveness to anti-leukemic therapies such as asparaginase and tyrosine kinase
inhibitors (Iwamoto et al., 2007; B. Zhang et al., 2013).
Our results extend this paradigm to the effect of 1, 25-(OH)2VD3 on growth and
migration of BCR-ABL+ ALL Arf-/- leukemia cells. 1, 25-(OH)2VD3 actively induced
bone marrow stroma to release CXCL12 in vitro, and increased CXCL12 serum levels in
vivo, resulting in an increased ability to attract the BCR-ABL+ Arf-/- ALL to the marrow
and support its growth. Different cell types in the bone marrow, other than hMSCs that
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Figure 4-18. Percentage of different CXCL12 expressing cells in bone marrow of
VD3-sufficient mice versus VD3-deficient mice.

Figure 4-19. Percentage of different CXCL12 expressing cells in bone tissue of
VD3-sufficient mice versus VD3-deficient mice.
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produce CXCL12 may also be responsive to 1, 25-(OH)2VD3 and increase the production
of chemokine CXCL12. Apart from hMSCs, in vivo multiple other cell types such as PaS
mesenchymal stem cells, osteoblasts, endothelial cells and CARs express CXCL12.
Above all, CARs express significant amount of CXCL12 in the bone marrow
microenvironment. In bone and bone marrow of vitamin D sufficient mice CAR cell
percentage is significantly higher compared to VD3 deficient mice. Our results suggest
that vitamin D not only can induce CXCL12 expression in vitro, but in vivo vitamin D
can significantly affect the number of CXCL12 expressing cells.
In vivo, vitamin D, in the presence of BCR-ABL+ Arf-/- leukemia, also
remodeled the bone marrow stroma, inducing expression of Type 1 and V collagens.
Others have reported that increased bone marrow reticulin and collagen fibers are
associated with malignant diseases and may anchor and trap the leukemic cells in the
marrow providing an environment where they become more drug resistant (Nath et al.,
2011). While this study probed the interaction of 1, 25-(OH)2VD3 signaling through the
co-cultured bone marrow stromal cells, in vivo multiple other cell types in the bone
marrow express VDR, including osteoblasts. Hence, in vivo, Vitamin D may signal
through VDR in additional cells in the bone and bone marrow influencing the
microenvironment and differentially altering the growth and viability of the leukemia
cells.
It will be important to determine if vitamin D levels significantly affect the
growth of BCR-ABL+ Arf-/- ALL in mice in vivo can be extended to other subtypes of
pediatric leukemia. Moreover, do these results in mice translate to humans? Interestingly,
a study in children that measured dietary vitamin D intake in newly diagnosed children
with ALL found that vitamin D intake was significantly different between patients who
presented with high-risk ALL versus standard risk ALL. Failure to meet daily dietary
amounts of vitamin D was higher in the standard risk versus high-risk patients, while the
proportion of patients who met the vitamin D dietary requirements was higher in the high
risk versus standard risk patients (Ladas et al., 2016). Clearly our findings suggest that
the clinical levels of vitamin D should be measured in leukemic patients over the course
of therapy to determine if there is an association in humans between vitamin sufficiency
and survival from different subtypes of leukemia, and if vitamin supplementation to
vitamin deficient patients affects survival from acute lymphoblastic leukemias.
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CHAPTER 5.

SUMMARY

The overall goal of this research work was to evaluate if vitamin D deficiency
could cause any vitamin – drug interaction with CYP3A4 substrates and if it has an effect
on survival outcome from B-ALL. We developed diet-based age-controlled vitamin D
sufficient and deficient mice and evaluated changes associated with vitamin D status on
intestinal, hepatic and renal drug metabolizing enzymes (CYP3A) and drug transporter
(PGP, BCRP, MRP4). We found that dietary vitamin D can alter mouse intestinal
Cyp3a11 and hCYP3A4 expression in female mice. Paradoxically, we also observed a
significant increase in intestinal transporter expression in both male and female vitamin D
deficient mice. However, these changes did not cause a significant vitamin drug
interaction with dexamethasone and dasatinib which are both CYP3A4 and PGP
substrates and given orally to ALL patients. However, we found that vitamin D sufficient
mice had markedly accelerated disease progression and decreased survival from BCRABL ALL compared to mice that were vitamin D deficient.
DEX is a potential inducer of CYP3A depending on the concentrations achieved
in the tissue. We calculated gut concentrations of DEX to be in sub-micromolar range
and can activate PXR to induce CYP3A genes. Utilizing intestinal and liver tissues from
DEX treated mice for 3.5 days, we analyzed the expression of CYP genes. Our results
suggest that, 3.5 days treatment of DEX has significantly induced multiple CYP3A genes
in the intestine of vitamin D deficient group but not the sufficient group. Moreover, we
analyzed the expression of CYP3A and CYP2B genes in the livers of DEX treated mice.
The plasma concentrations of DEX in this study was in nanomolar range, which can
activate GR but not PXR. We observed significant induction of CYP2B genes in all the
groups indicating GR activation in the livers.
When we placed vitamin D sufficient and deficient mice injected with BCR-ABL
ALL cells on discontinuous DEX regimen, despite the treatment, vitamin D sufficient
mice fared worse than the vitamin D deficient mice. This indicated that vitamin D itself
has an effect on BCR-ABL leukemia progression. Therefore, we next evaluated the
mechanisms by which vitamin D can affect leukemia cells.
Our studies show that BCR-ABL ALL cells do not express VDR, a receptor
through which vitamin D binds and regulates gene transcription. However, many cells in
the bone marrow microenvironment in which the lymphoblasts proliferate in vivo, such as
osteoblasts, endothelial cells and CARs express VDR. In vitro the BCR-ABL ALL cells
are co-cultured in with hMSCs, which act as a bone marrow micro-environment, and
these cells do express VDR. Co-culturing BCR-ABL cells with hMSCs and treating with
vitamin D directly increased the proliferation of BCR-ABL ALL cells and increased their
migration to co-cultured hMSCs. The increased migration of BCR-ABL ALL cells to
hMSCs was mediated by Vitamin D induction of CXCL12, an important chemokine for
leukemia cell proliferation and migration to hMSCs. In vivo, vitamin D, in the presence
of BCR-ABL+ Arf-/- leukemia, also remodeled the bone marrow stroma, inducing
expression of Type 1 and V collagens, and further increased the number of CARs
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(CXCL12 producing cells) in the bone and bone marrow. Consequently, Vitamin D may
signal through VDR in neighboring supportive cells in the bone and bone marrow,
remodeling the microenvironment and differentially altering the growth and viability of
the leukemia cells.
Our studies have highlighted that vitamin D deficiency has a significant effect on
survival outcome. Although many retrospective reports suggest the association of vitamin
D levels and cancer risk, since their primary end point was not overall survival or
mortality, it will be important to design individual clinical trials to ascertain the
association of vitamin D levels and survival outcome. Since many pediatric leukemia
patients are given vitamin D supplementation, it is important to understand the impact of
VD3 supplementation during chemotherapy on survival and drug efficacy in patients with
pre-B cell ALL. Further efforts are needed to elucidate vitamin D’s role and potential
utility in the clinical setting for different leukemia subtypes.
Clearly our findings suggest that the clinical levels of vitamin D should be
measured in leukemic patients over the course of therapy to determine if there is an
association in humans between vitamin sufficiency and survival from different subtypes
of acute lymphoblastic leukemia, and if vitamin supplementation to vitamin deficient
patients affects survival from acute lymphoblastic leukemias.
With vitamin D having a significant effect on BCR-ABL ALL cell proliferation
and migration, it will be important to determine if vitamin D levels also affect other
subtypes of pediatric leukemia. Moreover, there are many studies suggesting different
roles of vitamin D in mice versus humans. Thus, it will be important to study if these
results in mice translate to humans.
Our data demonstrate that dietary vitamin D can influence intestinal mouse
Cyp3a11 and human CYP3A4 expression. Given that the level of induction of CYP3A
genes is different between vitamin D deficient and sufficient mice, further studies
investigating possible drug-drug interactions that could arise when CYP3A4 drugs are
co-administered with DEX in vitamin D deficient condition could be of significant
importance. This data might help in better understanding of clinical situations where
multiple drugs are co-administered during various stages of chemotherapy.
The broad expression pattern and widespread effects of vitamin D signaling can
lead to unexpected outcomes and caution might be needed while supplementing patients
with vitamin D. Owing to the known pleiotropic roles of vitamin D, and taking into
consideration unexpected results from this study showing vitamin D deficient mice have
a survival advantage from ALL, as mentioned before it is important to study further
effects of vitamin D deficiency and supplementation in other B-cell leukemia subtypes
and other diseases. Vitamin D was shown to cause stromal cell remodeling in pancreatic
cancer (Sherman et al., 2014), fibrosis in hepatic stellate cancer (N. Ding et al., 2013) and
in this study altering the bone marrow microenvironment suggesting an indirect role of
vitamin D on disease outcome. Although it has been reported that high vitamin D levels
or intake of vitamin D reduces the risk of colorectal, breast cancer as well as type I
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diabetes, multiple sclerosis and hypertension (Holick & Chen, 2008), it is critical to
reevaluate any effects of vitamin D status on the disease progression and outcome as well
as to discern the mechanistic pathways altered by vitamin D status which directly or
indirectly can affect the disease outcome. This would be best performed through clinical
trials that would evaluate, first, whether vitamin D status (without supplementation)
effects disease progression or survival across ALL subtypes before beginning any
vitamin D therapeutic treatment in these patients.
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